U.S. patent application number 14/535640 was filed with the patent office on 2016-10-06 for compounds and methods for treating candidiasis and aspergillus infections.
The applicant listed for this patent is Cellceutix Corporation, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY. Invention is credited to Gill Diamond, Kathryn B. Freeman, Richard W. Scott, Haizhong Tang.
Application Number | 20160287586 14/535640 |
Document ID | / |
Family ID | 48799667 |
Filed Date | 2016-10-06 |
United States Patent
Application |
20160287586 |
Kind Code |
A1 |
Scott; Richard W. ; et
al. |
October 6, 2016 |
COMPOUNDS AND METHODS FOR TREATING CANDIDIASIS AND ASPERGILLUS
INFECTIONS
Abstract
The present disclosure provides compounds, or pharmaceutically
acceptable salts thereof, for killing or inhibiting the growth of a
Candida or Aspergillus species or preventing or treating a mammal
having candidiasis (oral and/or disseminated) or an Aspergillus
infection.
Inventors: |
Scott; Richard W.; (Radnor,
PA) ; Freeman; Kathryn B.; (Radnor, PA) ;
Tang; Haizhong; (Radnor, PA) ; Diamond; Gill;
(Newberry, FL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Cellceutix Corporation
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY |
BEVERLY
NEW BRUNSWICK |
MA
NJ |
US
US |
|
|
Family ID: |
48799667 |
Appl. No.: |
14/535640 |
Filed: |
November 7, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13744517 |
Jan 18, 2013 |
8895561 |
|
|
14535640 |
|
|
|
|
61698782 |
Sep 10, 2012 |
|
|
|
61604583 |
Feb 29, 2012 |
|
|
|
61587865 |
Jan 18, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07C 211/28 20130101;
C07D 239/28 20130101; A61K 31/381 20130101; A61K 31/505 20130101;
A61K 31/4436 20130101; A61K 31/496 20130101; A61K 31/506 20130101;
C07C 211/29 20130101; A61P 17/00 20180101; C07C 217/20 20130101;
C07D 277/28 20130101; A01N 25/00 20130101; C07D 333/76 20130101;
C07C 279/04 20130101; C07D 239/26 20130101; C07D 249/06 20130101;
A61K 9/06 20130101; C07D 239/38 20130101; C07C 237/08 20130101;
C07C 211/27 20130101; A61P 31/10 20180101; C07D 409/14 20130101;
C07C 279/12 20130101; C07D 307/52 20130101; C07D 209/86 20130101;
C07C 279/06 20130101; C07C 279/08 20130101; A61K 31/404 20130101;
A61K 31/4192 20130101; C07D 333/20 20130101; A61K 9/0053 20130101;
C07D 307/91 20130101 |
International
Class: |
A61K 31/506 20060101
A61K031/506; A61K 9/06 20060101 A61K009/06; A61K 9/00 20060101
A61K009/00 |
Goverment Interests
REFERENCE TO GOVERNMENT GRANTS
[0001] The present disclosure was supported by funds from the U.S.
Government (NIH/NIDCR Grant No. 2R44DE018371-02) and the Government
may therefore have certain rights in the disclosure.
Claims
1-76. (canceled)
77. A method of preventing or treating a human having oral or
disseminated candidiasis or an aspergillus infection comprising
administering to the human in need thereof an effective amount of a
compound of Formula IV: ##STR00135## wherein: R.sup.1 and R.sup.2
are, independently, --C(.dbd.NH)NH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.NH)NH.sub.2, where n is 2, 3, or 4; or a
pharmaceutically acceptable salt thereof.
78-252. (canceled)
253. The method of claim 77 wherein R.sup.1 and R.sup.2 are,
independently, --C(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.NH)NH.sub.2, where n is 2 or 3.
254. The method of claim 77 wherein R.sup.1 and R.sup.2 are,
independently, --C(.dbd.NH)NH.sub.2 or --(CH.sub.2).sub.nNH.sub.2,
where n is 2 or 3.
255. The method of claim 77 wherein the compound is: ##STR00136##
or a pharmaceutically acceptable salt thereof.
256. The method of claim 77 wherein the compound, or
pharmaceutically acceptable salt thereof, that is administered to
the human is in a pharmaceutical composition comprising a
pharmaceutically acceptable carrier.
257. The method of claim 256 wherein the pharmaceutical composition
is in a unit dosage form.
258. The method of claim 257 wherein the unit dosage form is a
packaged preparation.
259. The method of claim 257 wherein the unit dosage form is a
tablet or capsule.
260. The method of claim 77 wherein the human has oral or
disseminated candidiasis infection.
261. The method of claim 77 wherein the human has an aspergillus
infection.
Description
FIELD
[0002] The present disclosure is directed, in part, to compounds,
or pharmaceutically acceptable salts thereof, and pharmaceutical
compositions comprising the same, and methods for treating a mammal
having candidiasis, such as oral candidiasis and/or disseminated
candidiasis, and/or an aspergillus infection.
BACKGROUND
[0003] Candidiasis encompasses fungal infections caused by a
variety of species of the genus Candida, in particular mostly by
Candida albicans, which is a yeast-like fungus. Candida spp. are
normally present in the mouth, vagina, and intestines of healthy
individuals; normal bacteria in these areas keep the amount of
Candida spp. in check. Infection of candidal fungi normally depends
on a weakened immune status of an individual to invade tissue that
normally would be resistant to infection and the opportunity to
gain access to the circulatory system. Candida infections that
develop in immunocompromised individuals can affect the entire body
(e.g., disseminated or systemic candidiasis) and may become life
threatening. The most common condition is topical candidiasis
(fungus growing on the surface of the body). An example of this is
a common form of "diaper rash" in infants. Topical candidiasis can
affect the skin, the vagina, the mouth (e.g., oral candidiasis) and
the esophagus, and in immunocompromised individuals (e.g., HIV
patients).
[0004] Candida infections are opportunistic and generally begin
with increased colonization of the junction of mucous membranes and
skin surfaces of vulnerable parts of the body such as, for example,
oral, nasal, vaginal, and anal orifices, and the lining of the
respiratory tract. Under some abnormal conditions, including the
reduction of normal bacteria in a particular part of the body or
skin defects such as wounds, ulcerations, and burns, the fungi can
overgrow and cause infection of the outer layers of the skin and
mucous membranes. This may occur in the mouth (oral thrush), in the
vagina or penis (genital candidiasis), between folds and surfaces
of skin (intertrigo), and in and around the nails (paronychia and
onychomycosis).
[0005] In some instances, the fungus enters the bloodstream and
causes disseminated disease affecting internal body organs such as
the kidneys, spleen, lungs, liver, eyes, meninges, brain, and heart
valves. This condition is called systemic or disseminated
candidiasis; it can result in a range of diseases such as
superficial mucocutaneous disease, candidiasis of the liver and
spleen (hepatosplenic candidiasis), and peritonitis. This is
usually seen in patients who are seriously ill with other diseases
who have been receiving potent antibiotics that treat bacterial
infection.
[0006] Oral candidiasis (sometimes referred to as "thrush") is an
infection in which the fungus of the genus Candida (a yeast)
accumulates on the mucous membranes of the mouth. It is most often
caused by Candida albicans, or less commonly by Candida glabrata or
Candida tropicalis. If occurring in the mouth of a baby, the
candidiasis is commonly referred to as oral thrush, whereas if
occurring in the mouth or throat of an adult, it may also be termed
candidosis or moniliasis.
[0007] Oral infection by Candida species may not be immediately
noticeable but can develop suddenly and may persist for a long
time. The infection usually appears as thick white or cream-colored
deposits on mucosal membranes such as the tongue, inner cheeks,
gums, tonsils, and palate. The infected mucosa may appear inflamed
(red and possibly slightly raised) and sometimes have a cottage
cheese-like appearance. The lesions can be painful and may become
tender and often bleed if rubbed or scraped. Cracking at the
corners of the mouth, a cottony-like sensation inside the mouth,
and even temporary loss of taste can occur. In more severe cases,
the infection can spread down the esophagus and cause difficulty
swallowing, which is sometimes referred to as esophageal
candidiasis. Thrush does not usually cause a fever unless the
infection has spread beyond the esophagus to other body parts, such
as the lungs (i.e., systemic candidiasis).
[0008] Although oral thrush can affect anyone, it is more likely to
occur in babies and in people who wear dentures, use inhaled
corticosteroids, or have compromised immune systems. Oral thrush
and other Candida infections can occur when the immune system is
weakened by disease or drugs such as prednisone, or when
antibiotics disturb the natural balance of microorganisms in the
body. Normally, the immune system repels harmful invading
organisms, such as fungi, while maintaining a balance between
"good" and "bad" microbes that normally inhabit the body. When
these protective mechanisms fail, however, an oral thrush infection
may take hold.
[0009] The following diseases or conditions may make one more
susceptible to oral thrush infection:
[0010] 1) HIV/AIDS. The human immunodeficiency virus (HIV) damages
or destroys cells of the immune system, making one more susceptible
to opportunistic infections. Repeated bouts of oral thrush may be
the first sign of an HIV infection.
[0011] 2) Cancer. The immune system is likely to be weakened from
the disease and from treatments, such as chemotherapy and
radiation. Both the disease and treatments can increase the risk of
Candida infections such as oral thrush.
[0012] 3) Diabetes mellitus. In untreated or under-treated
diabetes, the saliva may contain large amounts of sugar, which
encourages the growth of Candida.
[0013] 4) Vaginal yeast infections. Vaginal yeast infections are
caused by the same fungus that causes oral thrash. Although a yeast
infection is not typically dangerous, a pregnant female can pass
the fungus to the baby during delivery.
[0014] Oral candidiasis can be treated with topical anti-fungal
drugs, such as nystatin, miconazole, Gentian violet, or
amphotericin B. Topical therapy is normally provided as an oral
suspension which is washed around the mouth and then swallowed by
the patient. Patients who are immunocompromised, either with
HIV/AIDS or as a result of chemotherapy, may require systemic
treatment with oral or intravenous administered anti-fungals. Some
anti-fungal medications, however, may cause liver damage. For this
reason, a physician will likely perform blood tests to monitor
liver function, especially if prolonged treatment is required or
there is a history of liver disease.
[0015] Some Aspergillus species cause serious disease in humans and
animals. The most common pathogenic species include Aspergillus
fumigatus and Aspergillus flavus. Aspergillus flavus produces
aflatoxin which is both a toxin and a carcinogen, and which can
contaminate foods. The most common causing allergic disease are
Aspergillus fumigatus and Aspergillus clavatus. Other species,
Aspergillus spp., are important agricultural pathogens.
SUMMARY
[0016] The present disclosure provides compounds of Formula I:
##STR00001##
wherein: each X is, independently, O, S, or S(.dbd.O).sub.2; each
R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
--C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each
p is, independently, 1 or 2; each R.sup.2 is, independently, H,
halo, --CF.sub.3, or --C(CH.sub.3).sub.3; each V.sup.2 is H, and
each V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.6 is H,
--S--(CH.sub.2).sub.m--NH.sub.2,
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2,
--O--(CH.sub.2).sub.m--NH.sub.2, or
--O--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof.
[0017] The present disclosure also provides compounds of Formula
II:
##STR00002##
wherein: R.sub.1 is H; R.sub.2 is --NH.sub.2; each R.sup.11 is,
independently, --(CH.sub.2).sub.0-4--R.sup.4 where R.sup.4 is
chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, --C.sub.3-C.sub.8cycloalkyl,
phenyl optionally substituted with one or more
--C.sub.1-C.sub.4alkyl groups, --C.sub.1-C.sub.4alkoxy groups, or
halo groups, and heteroaryl optionally substituted with one or more
--C.sub.1-C.sub.4alkyl groups, --C.sub.1-C.sub.4alkoxy groups, or
halo groups; each R.sub.9 is, independently, hydroxyethoxymethyl,
methoxyethoxymethyl, polyoxyethylene, or --(CH.sub.2).sub.q--V
where q is from 1 to 5, and each V is, independently, chosen from
amino, hydroxyl, --C.sub.1-C.sub.6alkylamino,
--C.sub.1-C.sub.6dialkylamino, --C.sub.1-C.sub.6alkylurea,
--NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine, phenyl optionally substituted with an amino,
--C.sub.1-C.sub.6alkylamino, or --C.sub.1-C.sub.6dialkylamino, and
lower acylamino optionally substituted with one or more amino,
lower alkylamino, or lower dialklylamino, where the alkylene chain
is optionally substituted with an amino or hydroxyl group; and m is
2 to at least about 30; or a pharmaceutically acceptable salt
thereof.
[0018] The present disclosure also provides compounds of Formula
III:
##STR00003##
wherein:
[0019] X is --C(R.sup.7)C(R.sup.8), --C(.dbd.O), N(R.sup.9), O, S,
S(.dbd.O), or S(.dbd.O).sub.2;
[0020] R.sup.7, R.sup.8, and R.sup.9 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, --OH,
--CF.sub.3, aromatic group, --(CH.sub.2).sub.qNH.sub.2, or
--(CH.sub.2).sub.qNHC(.dbd.NH)NH.sub.2, where q is 0 to 4;
[0021] R.sup.1 and R.sup.2 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, OH,
-haloC.sub.1-C.sub.8alkyl, --CN, or --CF.sub.3;
[0022] R.sup.3 and R.sup.4 are, independently, H or
-carbocycle(R.sup.5)(R.sup.6);
[0023] each R.sup.5 and each R.sup.6 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, amino, --OH,
--CF.sub.3, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, aromatic group, heterocycle, or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8;
[0024] provided that the compound is not Compound 116-134;
or a pharmaceutically acceptable salt thereof.
[0025] The present disclosure also provides compounds of Formula
IV;
##STR00004##
[0026] wherein;
[0027] R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.NH)NH.sub.2, where n is 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.
[0028] The present disclosure also provides compounds of Formula
V:
##STR00005##
wherein:
[0029] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0030] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0031] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0032] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, --CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0033] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0034] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0035] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
or a pharmaceutically acceptable salt thereof.
[0036] The present disclosure also provides compounds of Formula
VI:
##STR00006##
wherein:
[0037] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0038] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0039] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0040] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0041] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0042] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
or a pharmaceutically acceptable salt thereof.
[0043] The present disclosure also provides compounds of Formula
VII:
##STR00007##
wherein:
[0044] each R.sup.1 is, H, --C.sub.1-C.sub.8alkyl,
--C.sub.1-C.sub.8alkoxy, halo, --OH, --CF.sub.3, or --CN; and
[0045] each R.sup.2 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof.
[0046] The present disclosure also provides compounds of Formula
VIII:
##STR00008##
wherein:
[0047] R.sup.1 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0048] R.sup.2 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0049] R.sup.3 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0050] R.sup.4 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0051] R.sup.5 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, --C.ident.C--CH.sub.2NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0052] R.sup.6 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0053] R.sup.7 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0054] R.sup.8 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0055] R.sup.9 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
or a pharmaceutically acceptable salt thereof.
[0056] The present disclosure also provides compounds of Formula
IX:
##STR00009##
wherein:
[0057] each X is, independently, O or S;
[0058] each Y is, independently, O or S;
[0059] each R.sub.2 is, independently, --C.sub.1-C.sub.9 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
[0060] each R.sub.3 is, independently, --C.sub.1-C.sub.9 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
and
[0061] each R.sub.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0062] The present disclosure also provides compounds of Formula
X:
##STR00010##
wherein:
[0063] X is
##STR00011##
and
[0064] each R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0065] The present disclosure also provides pharmaceutical
compositions comprising any one or more of the foregoing compounds,
or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable carrier.
[0066] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with any
one or more of the foregoing compounds, or pharmaceutically
acceptable salt thereof.
[0067] The present disclosure also provides methods of preventing
or treating a mammal having candidiasis (oral and/or disseminated)
and/or an aspergillus infection comprising administering to the
mammal in need thereof an effective amount of any one or more of
the foregoing compounds, or pharmaceutically acceptable salt
thereof.
[0068] The present disclosure also provides any one or more of the
foregoing compounds, or pharmaceutically acceptable salts thereof,
for killing or inhibiting the growth of a Candida or Aspergillus
species or preventing or treating a mammal having candidiasis (oral
and/or disseminated) and/or an aspergillus infection.
[0069] The present disclosure also provides any one or more of the
foregoing compounds, or pharmaceutically acceptable salts thereof,
for use in the manufacture of a medicament for killing or
inhibiting the growth of a Candida or Aspergillus species or
preventing or treating a mammal having candidiasis (oral and/or
disseminated) and/or an aspergillus infection.
[0070] The present disclosure also provides uses of any one or more
of the foregoing compounds, or pharmaceutically acceptable salts
thereof, for killing or inhibiting the growth of a Candida or
Aspergillus species or preventing or treating a mammal having
candidiasis (oral and/or disseminated) and/or an aspergillus
infection.
[0071] The present disclosure also provides uses of any one or more
of the foregoing compounds, or pharmaceutically acceptable salts
thereof, in the manufacture of a medicament for killing or
inhibiting the growth of a Candida or Aspergillus species or
preventing or treating a mammal having candidiasis (oral and/or
disseminated) and/or an aspergillus infection.
BRIEF DESCRIPTION OF THE DRAWINGS
[0072] FIG. 1 shows results of screening over 800 compounds at a
single concentration of 10.mu.M against a clinical isolate of C.
albicans GDH2346 (triangles), and an additional 400 compounds with
11 concentrations to give an IC.sub.50 (see, green squares).
[0073] FIGS. 2A, 2B, 2C, and 2D show results of fluorescence
microscopy of C. albicans (GDH2346) hyphae treated with Compound
100 (8 .mu.g/mL) for 0 minutes (FIG. 2A), 15 minutes (FIG. 2B), 30
minutes (FIG. 2C), or 60 minutes (FIG. 2D).
[0074] FIGS. 3A and 3B show results of dose-dependent membrane
permeabilization of Candida, resulting in cellular accumulation of
PI evident within 30 minutes at 8 to 32 .mu.g/mL Compound 100
concentrations (FIG. 3A) and permeabilized after a 5-minute
treatment with Compound 100 at 32 .mu.g/mL (FIG. 3B).
[0075] FIGS. 4A, 4B, and 4C show results of cells treated with
either Compound 100 or Histatin 5; levels of intracellular and
extracellular ATP in cells (FIG. 4A); time-frame of ATP efflux
following treatment (FIG. 4B); and dose-dependent efflux over 30
minutes of exposure time (FIG. 4C).
[0076] FIGS. 5A and 5B show results of sterilization of infected
tongue following a single topical dose of Compound 100 or Nystatin
(FIG. 5A); and a photomicrograph of a 10 .mu.m section of a tongue
from an infected mouse on day 4, stained with PAS (FIG. 5B).
[0077] FIGS. 6A and 6B show cidal activity with rapid killing
kinetics of Compound 100 (FIG. 6A) and Compound 135 (FIG. 6B).
[0078] FIG. 7 shows results of cidal activity of Compound 135 with
.gtoreq.1.5 log.sub.10 reductions in tissue burden from treatment
onset.
[0079] FIG. 8 shows results of static activity with current
triazole and anti-fungals in a model.
[0080] FIG. 9 shows survival of mice over a 14-day period in a
disseminated Candidiasis survival study model in which neutropenic
mice inoculated with C. albicans in a tail vein.
DESCRIPTION OF EMBODIMENTS
[0081] The identification of a potent HDP mimetic (Compound 100),
inter alia, that exhibits rapid membrane-disrupting activity
against Candida albicans at low concentrations, using propidium
iodide uptake is demonstrated here. In contrast to Histatin 5,
Compound 100 treatment resulted in rapid efflux of ATP, and killing
occurred even in the presence of sodium azide, which prevents
membrane transport. Fluorescence microscopy, however, showed
incorporation of the compound into the cells, suggesting a
mechanism of self-promoted uptake. The compound also demonstrated a
significant reduction of metabolic activity in mature biofilms of
C. albicans grown at an air-liquid interface. To examine the
activity of Compound 100 in vivo, an oral model of Candida
infection was established in C57BI/6 mice. Animals were first
treated for 5 days with oral tetracycline to reduce normal oral
flora. An infection was initiated in the mice by inoculating a 50
.mu.L suspension of C. albicans onto lightly scored tongues. This
led to colonization of the tongues by days 2 to 4 after inoculation
as measured by histological analysis and by recovery of viable
colonies upon homogenization. Topical treatment of the infections
on day 3 with a single 50 .mu.L dose of a 1 mg/mL compound solution
in a neutral hydrogel was sufficient to reduce the total colony
counts by greater than 10-fold, equivalent to a similar treatment
with an equivalent concentration of Nystatin suspension. These
results, as well as those presented herein, suggest that the
compounds described herein represent a strong potential source of
fungicidal drugs.
[0082] Unless defined otherwise, all technical and scientific terms
have the same meaning as is commonly understood by one of ordinary
skill in the art to which the embodiments disclosed belongs.
[0083] As used herein, the terms "a" or "an" means that "at least
one" or "one or more" unless the context clearly indicates
otherwise.
[0084] As used herein, the term "about" means that the numerical
value is approximate and small variations would not significantly
affect the practice of the disclosed embodiments. Where a numerical
limitation is used, unless indicated otherwise by the context,
"about" means the numerical value can vary by .+-.10% and remain
within the scope of the disclosed embodiments.
[0085] As used herein, the term "acylamino" means an amino group
substituted by an acyl group (e.g., --O--C(.dbd.O)--H or
--O--C(.dbd.O)-alkyl. An example of an acylamino is --NHC(.dbd.O)H
or --NHC(.dbd.O)CH.sub.3. The term "lower acylamino" refers to an
amino group substituted by a lower acyl group (e.g.,
--O--C(.dbd.O)--H or --O--C(.dbd.O)--C.sub.1-6alkyl). An example of
a lower acylamino is --NHC(.dbd.O)H or --NHC(.dbd.O)CH.sub.3.
[0086] As used herein, the term "alkenyl" means a straight or
branched alkyl group having one or more double carbon-carbon bonds
and 2-20 carbon atoms, including, but not limited to, ethenyl,
1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl,
and the like. In some embodiments, the alkenyl chain is from 2 to
10 carbon atoms in length, from 2 to 8 carbon atoms in length, from
2 to 6 carbon atoms in length, or from 2 to 4 carbon atoms in
length.
[0087] As used herein, the term "alkoxy" means a straight or
branched --O-alkyl group of 1 to 20 carbon atoms, including, but
not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, t-butoxy,
and the like. In some embodiments, the alkoxy chain is from 1 to 10
carbon atoms in length, from 1 to 8 carbon atoms in length, from 1
to 6 carbon atoms in length, from 1 to 4 carbon atoms in length,
from 2 to 10 carbon atoms in length, from 2 to 8 carbon atoms in
length.
[0088] As used herein, the term"alkyl" means a saturated
hydrocarbon group which is straight-chained or branched. An alkyl
group can contain from 1 to 20, from 2 to 20, from 1 to 10, from 2
to 10, from 1 to 8, from 2 to 8, from 1 to 6, from 2 to 6, from 1
to 4, from 2 to 4, from 1 to 3, or 2 or 3 carbon atoms. Examples of
alkyl groups include, but are not limited to, methyl (Me), ethyl
(Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl,
t-butyl, isobutyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl,
hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl,
2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl,
2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl,
3-methyl-1-butyl, 2-methyl-3-butyl, 2-methyl-1-pentyl,
2,2-dimethyl-1-propyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl,
2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl,
2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, and
the like.
[0089] As used herein, the term "alkylamino" means an amino group
substituted by an alkyl group having from 1 to 6 carbon atoms. An
example of an alkylamino is --NHCH.sub.2CH.sub.3.
[0090] As used herein, the term "alkylene" or "alkylenyl" means a
divalent alkyl linking group. An example of an alkylene (or
alkylenyl) is methylene or methylenyl (--CH.sub.2--).
[0091] As used herein, the term "alkylthio" means an --S-alkyl
group having from 1 to 6 carbon atoms. An example of an alkylthio
group is --SCH.sub.2CH.sub.3.
[0092] As used herein, the term "alkynyl" means a straight or
branched alkyl group having one or more triple carbon-carbon bonds
and 2-20 carbon atoms, including, but not limited to, acetylene,
1-propylene, 2-propylene, and the like. In some embodiments, the
alkynyl chain is 2 to 10 carbon atoms in length, from 2 to 8 carbon
atoms in length, from 2 to 6 carbon atoms in length, or from 2 to 4
carbon atoms in length.
[0093] As used herein, the term "amidino" means
--C(.dbd.NH)NH.sub.2.
[0094] As used herein, the term "amino" means --NH.sub.2.
[0095] As used herein, the term "aminoalkoxy" means an alkoxy group
substituted by an amino group. An example of an aminoalkoxy is
--OCH.sub.2CH.sub.2NH.sub.2.
[0096] As used herein, the term "aminoalkyl" means an alkyl group
substituted by an amino group. An example of an aminoalkyl is
--CH.sub.2CH.sub.2NH.sub.2.
[0097] As used herein, the term "aminosulfonyl" means
--S(.dbd.O).sub.2NH.sub.2.
[0098] As used herein, the term "aminoalkylthio" means an alkylthio
group substituted by an amino group. An example of an
aminoalkylthio is --SCH.sub.2CH.sub.2NH.sub.2.
[0099] As used herein, the term "amphiphilic" means a
three-dimensional structure having discrete hydrophobic and
hydrophilic regions. An amphiphilic compound suitably has the
presence of both hydrophobic and hydrophilic elements.
[0100] As used herein, the term "animal" includes, but is not
limited to, humans and non-human vertebrates such as wild,
domestic, and farm animals.
[0101] As used herein, the phrase "an effective amount" of a
compound can be measured by the effectiveness of the compound. In
some embodiments, an effective amount inhibits growth of a
particular Candida or Aspergillus species by at least 10%, by at
least 20%, by at least 30%, by at least 40%, by at least 50%, by at
least 60%, by at least 70%, by at least 80%, by at least 90%, or by
at least 95%. In some embodiments, "an effective amount" is also a
"therapeutically effective amount" whereby the compound reduces or
eliminates at least one harmful effect of a Candida or Aspergillus
species on a mammal.
[0102] As used herein, the term "aryl" means a monocyclic,
bicyclic, or polycystic (e.g., having 2, 3 or 4 fused rings)
aromatic hydrocarbons. In some embodiments, aryl groups have from 6
to 20 carbon atoms or from 6 to 10 carbon atoms. Examples of aryl
groups include, but are not limited to, phenyl, naphthyl,
anthracenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthyl,
and the like.
[0103] As used herein, the term "arylalkyl" means a C.sub.1-6alkyl
substituted by aryl.
[0104] As used herein, the term "arylamino" means an amino group
substituted by an aryl group. An example of an arylamino is
--NH(phenyl).
[0105] As used herein, the term "arylene" means an aryl linking
group, i.e. an aryl group that links one group to another group in
a molecule.
[0106] As used herein, the term "candidiasis" means a yeast
infection of a Candida species. Types of candidiasis include, local
infections such as, for example, oral thrush or oral candidiasis,
genital candidiasis, intertrigo, paronychia, and onychomycosis, as
well as disseminated, candidiasis.
[0107] As used herein, the term "carbocycle" means a 5- or
6-membered, saturated or unsaturated cyclic ring, optionally
containing O, S, or N atoms as part of the ring. Examples of
carbocycles include, but are not limited to, cyclopentyl,
cyclohexyl, cyclopenta-1,3-diene, phenyl, and any of the
heterocycles recited above.
[0108] As used herein, the term "carrier" means a diluent,
adjuvant, or excipient with which a compound is administered.
Pharmaceutical carriers can be liquids, such as water and oils,
including those of petroleum, animal, vegetable or synthetic
origin, such as peanut oil, soybean oil, mineral oil, sesame oil
and the like. The pharmaceutical carriers can also be saline, gum
acacia, gelatin, starch paste, talc, keratin, colloidal silica,
urea, and the like. In addition, auxiliary, stabilizing,
thickening, lubricating and coloring agents can be used.
[0109] As used herein, the term "chemically nonequivalent termini"
means a functional group such as an ester, amide, sufonamide, or
N-hydroxyoxime that, when reversing the orientation of the
functional group (e.g., --(C.dbd.O)O--) produces different chemical
entities (e.g., --R.sup.1C(.dbd.O)OR.sup.2- vs.
-R.sup.1OC(.dbd.O)R.sup.2-).
[0110] As used herein, the term, "compound" means all
stereoisomers, tautomers, and isotopes of the compounds described
herein.
[0111] As used herein, the terms "comprising" (and any form of
comprising, such as "comprise", "comprises", and "comprised"),
"having" (and any form of having, such as "have" and "has"),
"including" (and any form of including, such as "includes" and
"include"), or "containing" (and any form of containing, such as
"contains" and "contain"), are inclusive or open-ended and do not
exclude additional, unrecited elements or method steps.
[0112] As used herein, the term "cyano" means --CN.
[0113] As used herein, the term "cycloalkyl" means non-aromatic
cyclic hydrocarbons including a cyclized alkyl, alkenyl, and
alkynyl groups that contain up to 20 ring-forming carbon atoms.
Cycloalkyl groups can include mono- or polycyclic ring systems such
as fused ring systems, bridged ring systems, and spiro ring
systems. In some embodiments, polycyclic ring systems include 2, 3
or 4 fused rings. A cycloalkyl group can contain from 3 to 15, from
3 to 10, from 3 to 8, from 3 to 6, from 4 to 6, from 3 to 5, or 5
or 6 ring-forming carbon atoms. Ring-forming carbon atoms of a
cycloalkyl group can be optionally substituted by oxo or sulfido.
Examples of cycloalkyl groups include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclooctyl, cyclononyl, cyclopentenyl, cyclohexenyl,
cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl,
adamantyl, and the like. Also included in the definition of
cycloalkyl are moieties that have one or more aromatic rings fused
(having a bond in common with) to the cycloalkyl ring, for example,
benzo or thienyl derivatives of pentane, pentene, hexane, and the
like (e.g., 2,3-dihydro-1H-indene-1-yl, or
1H-inden-2(3H)-one-1-yl).
[0114] As used herein, the term"dialkylamino" means an amino group
substituted by two alkyl groups, each having from 1 to 6 carbon
atoms.
[0115] As used herein, the term "facially amphiphilic" or "facial
amphiphilicity" means compounds with polar (hydrophilic) and
nonpolar (hydrophobic) side chains that adopt conformation(s)
leading to segregation of polar and nonpolar side chains to
opposite faces or separate regions of the structure or
molecule.
[0116] As used herein, the phrase "groups with chemically
nonequivalent termini" means functional groups such as esters
amides, sulfonamides and N-hydroxyoximes where reversing the
orientation of the substituents, e.g. R.sup.1C(.dbd.O)OR.sup.2 vs.
R.sup.1O(O.dbd.)CR.sup.2, produces unique chemical entities.
[0117] As used herein, the term "guanidino" means
--NH(.dbd.NH)NH.sub.2.
[0118] As used herein, the term "halo" means halogen groups
including, but not limited to fluoro, chloro, bromo, and iodo.
[0119] As used herein, the term "haloalkoxy" means an --O-haloalkyl
group. An example of an haloalkoxy group is OCF.sub.3.
[0120] As used herein, the term "haloalkyl" means a C.sub.1-6alkyl
group having one or more halogen substituents. Examples of
haloalkyl groups include, but are not limited to, --CF.sub.3,
--C.sub.2F.sub.5, --CHF.sub.2, --CCl.sub.3, --CHCl.sub.2,
--C.sub.2Cl.sub.5, --CH.sub.2CF.sub.3, and the like.
[0121] As used herein, the term "heteroaryl" means an aromatic
heterocycle having up to 20 ring-forming atoms (e.g., C) and having
at least one heteroatom ring member (ring-forming atom) such as
sulfur, oxygen, or nitrogen. In some embodiments, the heteroaryl
group has at least one or more heteroatoms ring-forming atoms, each
of which are, independently, sulfur, oxygen, or nitrogen. In some
embodiments, the heteroaryl group has from 3 to 20 ring-forming
atoms, from 3 to 10 ring-forming atoms, from 3 to 6 ring-forming
atoms, or from 3 to 5 ring-forming atoms. In some embodiments, the
heteroaryl group contains 2 to 14 carbon atoms, from 2 to 7 carbon
atoms, or 5 or 6 carbon atoms. In some embodiments, the heteroaryl
group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 or 2
heteroatoms. Heteroaryl groups include monocyclic and polycyclic
(e.g., having 2, 3 or 4 fused rings) systems. Examples of
heteroaryl groups include, but are not limited to, pyridyl,
pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl,
isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl (such as
indol-3-yl), pyrryl, oxazolyl, benzofuryl, benzothienyl,
benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl,
indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl,
carbazolyl, benzimidazolyl, indolinyl, pyranyl, oxadiazolyl,
isoxazolyl, triazolyl, thianthrenyl, pyrazolyl, indolizinyl,
isoindolyl, isobenzofuranyl, benzoxazolyl, xanthenyl, 2H-pyrrolyl,
pyrrolyl, 3H-indolyl, 4H-quinolizinyl, phthalazinyl,
naphthyridinyl, quinazolinyl, phenanthridinyl, acridinyl,
perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl,
phenothiazinyl, isoxazolyl, furazanyl, phenoxazinyl groups, and the
like. Suitable heteroaryl groups include 1,2,3-triazole,
1,2,4-triazole, 5-amino-1,2,4-triazole, imidazole, oxazole,
isoxazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole,
3-amino-1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole,
pyridine, and 2-aminopyridine.
[0122] As used herein, the term "heteroarylalkyl" means a
C.sub.1-6alkyl group substituted by a heteroaryl group.
[0123] As used herein, the term "heteroarylamino" means an amino
group substituted by a heteroaryl group. An example of a
heteroarylamino is --NH-(2-pyridyl).
[0124] As used herein, the term "heteroarylene" means a heteroaryl
linking group, i.e., a heteroaryl group that links one group to
another group in a molecule.
[0125] As used herein, the term "heterocycle" or "heterocyclic
ring" means a 5- to 7-membered mono- or bicyclic or 7- to
10-membered bicyclic heterocyclic ring system any ring of which may
be saturated or unsaturated, and which consists of carbon atoms and
from one to three heteroatoms chosen from N, O and S, and wherein
the N and S heteroatoms may optionally be oxidized, and the N
heteroatom may optionally be quaternized, and including any
bicyclic group in which any of the above-defined heterocyclic rings
is fused to a benzene ring. Particularly useful rings containing
one oxygen or sulfur, one to three nitrogen atoms, or one oxygen or
sulfur combined with one or two nitrogen atoms. The heterocyclic
ring may be attached at any heteroatom or carbon atom which results
in the creation of a stable structure. Examples of heterocyclic
groups include, but are not limited to, piperidinyl, piperazinyl,
2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl,
2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl,
pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,
pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl,
oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl,
thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl,
indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl,
benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl,
tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl,
thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and
oxadiazolyl. Morpholino is the same as morpholinyl.
[0126] As used herein, the term "heterocycloalkyl" means
non-aromatic heterocycles having up to 20 ring-forming atoms
including cyclized alkyl, alkenyl, and alkynyl groups, where one or
more of the ring-forming carbon atoms is replaced by a heteroatom
such as O, N, or S atom. Hetercycloalkyl groups can be mono or
polycyclic (e.g., fused, bridged, or spiro systems). In some
embodiments, the heterocycloalkyl group has from 1 to 20 carbon
atoms, or from 3 to 20 carbon atoms. In some embodiments, the
heterocycloalkyl group contains 3 to 14 ring-forming atoms, 3 to 7
ring-forming atoms, or 5 or 6 ring-forming atoms. In some
embodiments, the heterocycloalkyl group has 1 to 4 heteroatoms, 1
to 3 heteroatoms, or 1 or 2 heteroatoms. In some embodiments, the
heterocycloalkyl group contains 0 to 3 double bonds. In some
embodiments, the heterocycloalkyl group contains 0 to 2 triple
bonds. Examples of heterocycloalkyl groups include, but are not
limited to, morpholino, thiomorpholino, piperazinyl,
tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihydrobenzofuryl,
1,3-benzodioxole, benzo-1,4-dioxane, piperidinyl, pyrrolidinyl,
isoxazolidinyl, oxazolidinyl, isothiazolidinyl, pyrazolidinyl,
thiazolidinyl, imidazolidinyl, pyrrolidin-2-one-3-yl, and the like.
In addition, ring-forming carbon atoms and heteroatoms of a
heterocycloalkyl group can be optionally substituted by oxo or
sulfido. For example, a ring-forming S atom can be substituted by 1
or 2 oxo (form a S(O) or S(O).sub.2). For another example, a
ring-forming C atom can be substituted by oxo (form carbonyl). Also
included in the definition of heterocycloalkyl are moieties that
have one or more aromatic rings fused (having a bond in common
with) to the nonaromatic heterocyclic ring including, but not
limited to, pyridinyl, thiophenyl, phthalimidyl, naphthalimidyl,
and benzo derivatives of heterocycles such as indolene,
isoindolene, 4,5,6,7-tetrahydrothieno[2,3-c]pyridine-5-yl,
5,6-dihydrothieno[2,3-c]pyridin-7(4H)-one-5-yl,
isoindolin-1-one-3-yl, and 3,4-dihydroisoquinolin-1(2H)-one-3yl
groups. Ring-forming carbon atoms and heteroatoms of the
heterocycloalkyl group can be optionally substituted by oxo or
sulfido.
[0127] As used herein, the term "hydroxy" or "hydroxyl" means an
--OH group.
[0128] As used herein, the term "hydroxyalkyl" or "hydroxylalkyl"
means an alkyl group substituted by a hydroxyl group. Examples of a
hydroxyalkyl include, but are not limited to, --CH.sub.2OH and
--CH.sub.2CH.sub.2OH.
[0129] As used herein, the term "individual" or "patient," used
interchangeably, means any animal, including mammals, such as mice,
rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep,
horses, or primates, such as humans.
[0130] As used herein, the phrase "inhibiting the growth" means
reducing by any measurable amount the growth of one or more yeast
or mold, such as a Candida or Aspergillus species. In some
embodiments, the inhibition of growth may result in cell death of
the yeast or mold.
[0131] As used herein, the phrase "in need thereof" means that the
animal or mammal has been identified as having a need for the
particular method or treatment. In some embodiments, the
identification can be by any means of diagnosis. In any of the
methods and treatments described herein, the animal or mammal can
be in need thereof. In some embodiments, the animal or mammal is in
an environment or will be traveling to an environment in which a
particular disease, disorder, or condition is prevelant.
[0132] As used herein, the phrase "integer from 1 to 5" means 1, 2,
3, 4, or 5.
[0133] As used herein, the term "isolated" means that the compounds
described herein are separated from other components of either (a)
a natural source, such as a plant or cell, such as a bacterial
culture, or (b) a synthetic organic chemical reaction mixture, such
as by conventional techniques.
[0134] As used herein, the term "mammal" means a rodent (i.e., a
mouse, a rat, or a guinea pig), a monkey, a cat, a dog, a cow, a
horse, a pig, or a human. In some embodiments, the mammal is a
human.
[0135] As used herein, the term"nitro" means --NO.sub.2.
[0136] As used herein, the term "n-membered", where n is an
integer, typically describes the number of ring-forming atoms in a
moiety, where the number of ring-forming atoms is n. For example,
pyridine is an example of a 6-membered heteroaryl ring and
thiophene is an example of a 5-membered heteroaryl ring.
[0137] As used used herein, the phrase "optionally substituted"
means that substitution is optional and therefore includes both
unsubstituted and substituted atoms and moieties. A "substituted"
atom or moiety indicates that any hydrogen on the designated atom
or moiety can be replaced with a selection from the indicated
substituent groups, provided that the normal valency of the
designated atom or moiety is not exceeded, and that the
substitution results in a stable compound. For example, if a methyl
group is optionally substituted, then 3 hydrogen atoms on the
carbon atom can be replaced with substituent groups.
[0138] As used herein, the phrase "pharmaceutically acceptable"
means those compounds, materials, compositions, and/or dosage forms
which are, within the scope of sound medical judgment, suitable for
use in contact with tissues of humans and animals. In some
embodiments, "pharmaceutically acceptable" means approved by a
regulatory agency of the Federal or a state government or listed in
the U.S. Pharmacopeia or other generally recognized pharmacopeia
for use in animals, and more particularly in humans.
[0139] As used herein, the phrase "pharmaceutically acceptable
salt(s)," includes, but is not limited to, salts of acidic or basic
groups. Compounds that are basic in nature are capable of forming a
wide variety of salts with various inorganic and organic acids.
Acids that may be used to prepare pharmaceutically acceptable acid
addition salts of such basic compounds are those that form
non-toxic acid addition salts, i.e., salts containing
pharmacologically acceptable anions including, but not limited to,
sulfuric, thiosulfuric, citric, maleic, acetic, oxalic,
hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate,
bisulfate, bisulfite, phosphate, acid phosphate, isonicotinate,
borate, acetate, lactate, salicylate, citrate, acid citrate,
tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate,
succinate, maleate, gentisinate, fumarate, gluconate, glucaronate,
saccharate, formate, benzoate, glutamate, methanesulfonate,
ethanesulfonate, benzenesulfonate, p-toluenesulfonate, bicarbonate,
malonate, mesylate, esylate, napsydisylate, tosylate, besylate,
orthophoshate, trifluoroacetate, and pamoate (i.e.,
1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds that
include an amino moiety may form pharmaceutically acceptable salts
with various amino acids, in addition to the acids mentioned above.
Compounds that are acidic in nature are capable of forming base
salts with various pharmacologically acceptable cations. Examples
of such salts include, but are not limited to, alkali metal or
alkaline earth metal salts and, particularly, calcium, magnesium,
ammonium, sodium, lithium, zinc, potassium, and iron salts. The
present disclosure also includes quaternary ammonium salts of the
compounds described herein, where the compounds have one or more
tertiary amine moiety.
[0140] As used herein, the term "phenyl" means --C.sub.6H.sub.5. A
phenyl group can be unsubstituted or substituted with one, two, or
three suitable substituents.
[0141] As used herein, the terms "prevention" or "preventing" mean
a reduction of the risk of acquiring a particular disease,
condition, or disorder.
[0142] As used herein, the term "prodrug" means a derivative of a
known direct acting drug, which derivative has enhanced delivery
characteristics and therapeutic value as compared to the drug, and
is transformed into the active drug by an enzymatic or chemical
process.
[0143] As used herein, the term "purified" means that when
isolated, the isolate contains at least 90%, at least 95%, at least
98%, or at least 99% of a compound described herein by weight of
the isolate.
[0144] As used herein, the phrase "quaternary ammonium salts" means
derivatives of the disclosed compounds with one or more tertiary
amine moieties wherein at least one of the tertiary amine moieties
in the parent compound is modified by converting the tertiary amine
moiety to a quaternary ammonium cation via alkylation (and the
cations are balanced by anions such as Cl.sup.-, CH.sub.3COO.sup.-,
and CF.sub.3COO.sup.-), for example methylation or ethylation.
[0145] As used herein, the term "semicarbazone" means
.dbd.NNHC(.dbd.O)NH.sub.2.
[0146] As used herein, the phrase "solubilizing agent" means agents
that result in formation of a micellar solution or a true solution
of the drug.
[0147] As used herein, the term "solution/suspension" means a
liquid composition wherein a first portion of the active agent is
present in solution and a second portion of the active agent is
present in particulate form, in suspension in a liquid matrix.
[0148] As used herein, the phrase "substantially isolated" means a
compound that is at least partially or substantially separated from
the environment in which it is formed or detected.
[0149] As used herein, the phrase "suitable substituent" or
"substituent" means a group that does not nullify the synthetic or
pharmaceutical utility of the compounds described herein or the
intermediates useful for preparing them. Examples of suitable
substituents include, but are not limited to:
--C.sub.1-C.sub.6alkyl, --C.sub.1-C.sub.6alkenyl,
--C.sub.1-C.sub.6alkynyl, --C.sub.5-C.sub.6aryl,
--C.sub.1-C.sub.6alkoxy, --C.sub.3-C.sub.5heteroaryl,
--C.sub.3-C.sub.6cycloalkyl, --C.sub.5-C.sub.6aryloxy, --CN, --OH,
oxo, halo, haloalkyl, --NO.sub.2, --C(.dbd.O)OH, --NH.sub.2,
--NH(C.sub.1-C.sub.8alkyl), --N(C.sub.1-C.sub.8alkyl).sub.2,
--NH(C.sub.6aryl), --N(C.sub.5-C.sub.6aryl).sub.2, --C(.dbd.O)H,
--C(.dbd.O)(C.sub.1-C.sub.6alkyl),
--C(.dbd.O)(C.sub.5-C.sub.6aryl),
--C(.dbd.)--O--((C.sub.1-C.sub.6)alkyl), and
--C(.dbd.O)--O--((C.sub.5-C.sub.6)aryl. Any of the compounds herein
may be further substituted at, for example, open positions (such as
on a ring structure) by any of these substituents as desired by one
skilled in the art. One of skill in art can readily choose a
suitable substituent based on the stability and pharmacological and
synthetic activity of the compounds described herein.
[0150] As used herein, the phrase "therapeutically effective
amount" means the amount of active compound or pharmaceutical agent
that elicits the biological or medicinal response that is being
sought in a tissue, system, animal, individual or human by a
researcher, veterinarian, medical doctor or other clinician. The
therapeutic effect is dependent upon the disorder being treated or
the biological effect desired. As such, the therapeutic effect can
be a decrease in the severity of symptoms associated with the
disorder and/or inhibition (partial or complete) of progression of
the disorder, or improved treatment, healing, prevention or
elimination of a disorder, or side-effects. The amount needed to
elicit the therapeutic response can be determined based on the age,
health, size and sex of the subject. Optimal amounts can also be
determined based on monitoring of the subject's response to
treatment.
[0151] As used herein, the terms "treat," "treated," or "treating"
mean both therapeutic treatment and prophylactic or preventative
measures wherein the object is to prevent or slow down (lessen) an
undesired physiological condition, disorder or disease, or obtain
beneficial or desired clinical results. For purposes herein,
beneficial or desired clinical results include, but are not limited
to, alleviation of symptoms; diminishment of extent of condition,
disorder or disease; stabilized (i.e., not worsening) state of
condition, disorder or disease; delay in onset or slowing of
condition, disorder or disease progression; amelioration of the
condition, disorder or disease state or remission (whether partial
or total), whether detectable or undetectable; an amelioration of
at least one measurable physical parameter, not necessarily
discernible by the patient; or enhancement or improvement of
condition, disorder or disease. Treatment includes eliciting a
clinically significant response without excessive levels of side
effects. Treatment also includes prolonging survival as compared to
expected survival if not receiving treatment.
[0152] At various places in the present specification, substituents
of compounds may be disclosed in groups or in ranges. It is
specifically intended that the disclosure include each and every
individual subcombination of the members of such groups and ranges.
For example, the term "C.sub.1-6alkyl" is specifically intended to
individually disclose methyl, ethyl, propyl, C.sub.4alkyl,
C.sub.5alkyl, and C.sub.6alkyl.
[0153] For compounds in which a variable appears more than once,
each variable can be a different moiety selected from the Markush
group defining the variable. For example, where a structure is
described having two R groups that are simultaneously present on
the same compound, the two R groups can represent different
moieties selected from the Markush groups defined for R. In another
example, when an optionally multiple substituent is designated in
the form, for example,
##STR00012##
then it is understood that substituent R can occur s number of
times on the ring, and R can be a different moiety at each
occurrence. Further, in the above example, where the variable
T.sup.1 is defined to include hydrogens, such as when T.sup.1 is
CH.sub.2, NH, etc., any H can be replaced with a suitable
substituent.
[0154] It is further appreciated that certain features of the
disclosure, which are, for clarity, described in the context of
separate embodiments, can also be provided in combination in a
single embodiment. Conversely, various features of the disclosure
which are, for brevity, described in the context of a single
embodiment, can also be provided separately or in any suitable
subcombination.
[0155] It is understood that the present disclosure encompasses the
use, where applicable, of stereoisomers, diastereomers and optical
stereoisomers of the compounds described herein, as well as
mixtures thereof. Additionally, it is understood that
stereoisomers, diastereomers, and optical stereoisomers of the
compounds described herein, and mixtures thereof, are within the
scope of the present disclosure. By way of non-limiting example,
the mixture may be a racemate or the mixture may comprise unequal
proportions of one particular stereoisomer over the other.
Additionally, the compounds can be provided as a substantially pure
stereoisomers, diastereomers and optical stereoisomers (such as
epimers).
[0156] The compounds described herein can be asymmetric (e.g.,
having one or more stereocenters). All stereoisomers, such as
enantiomers and diastereomers, are intended to be included within
the scope of the present disclosure unless otherwise indicated.
Compounds that contain asymmetrically substituted carbon atoms can
be isolated in optically active or racemic forms. Methods of
preparation of optically active forms from optically active
starting materials are known in the art, such as by resolution of
racemic mixtures or by stereoselective synthesis. Many geometric
isomers of olefins, C.dbd.N double bonds, and the like can also be
present in the compounds described herein, and all such stable
isomers are contemplated in the present disclosure. Cis and trans
geometric isomers of the compounds are also included within the
scope of the disclosure and can be isolated as a mixture of isomers
or as separated isomeric forms. Where a compound capable of
stereoisomerism or geometric isomerism is designated in its
structure or name without reference to specific R/S or cis/trans
configurations, it is intended that all such isomers are
contemplated.
[0157] Resolution of racemic mixtures of compounds can be carried
out by any of numerous methods known in the art, including, for
example, fractional recrystallization using a chiral resolving acid
which is an optically active, salt-forming organic acid. Suitable
resolving agents for fractional recrystallization methods include,
but are not limited to, optically active acids, such as the D and L
forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric
acid, mandelic acid, malic acid, lactic acid, and the various
optically active camphorsulfonic acids such as
.beta.-camphorsulfonic acid. Other resolving agents suitable for
fractional crystallization methods include, but are not limited to,
stereoisomerically pure forms of .alpha.-methylbenzylamine (e.g., S
and R forms, or diastereomerically pure forms), 2-phenylglycinol,
norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine,
1,2-diaminocyclohexane, and the like. Resolution of racemic
mixtures can also be carried out by elution on a column packed with
an optically active resolving agent (e.g.,
dinitrobenzoylphenylglycine). Suitable elution solvent compositions
can be determined by one skilled in the art.
[0158] Compounds may also include tautomeric forms. Tautomeric
forms result from the swapping of a single bond with an adjacent
double bond together with the concomitant migration of a proton.
Tautomeric forms include prototropic tautomers which are isomeric
protonation states having the same empirical formula and total
charge. Examples of prototropic tautomers include, but are not
limited to, ketone-enol pairs, amide-imidic acid pairs,
lactam-lactim pairs, amide-imidic acid pairs, enamine-imine pairs,
and annular forms where a proton can occupy two or more positions
of a heterocyclic system including, but not limited to, 1H- and
3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole,
and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or
sterically locked into one form by appropriate substitution.
[0159] Compounds also include hydrates and solvates, as well as
anhydrous and non-solvated forms.
[0160] Compounds can also include all isotopes of atoms occurring
in the intermediates or final compounds. Isotopes include those
atoms having the same atomic number but different mass numbers. For
example, isotopes of hydrogen include tritium and deuterium.
[0161] In some embodiments, the compounds, or salts thereof, are
substantially isolated. Partial separation can include, for
example, a composition enriched in the compound described herein.
Substantial separation can include compositions containing at least
about 50%, at least about 60%, at least about 70%, at least about
80%, at least about 90%, at least about 95%, at least about 97%, or
at least about 99% by weight of the compound, or salt thereof.
Methods for isolating compounds and their salts are routine in the
art.
[0162] Although the disclosed compounds are suitable, other
functional groups can be incorporated into the compound with an
expectation of similar results. In particular, thioamides and
thioesters are anticipated to have very similar properties. The
distance between aromatic rings can impact the geometrical pattern
of the compound and this distance can be altered by incorporating
aliphatic chains of varying length, which can be optionally
substituted or can comprise an amino acid, a dicarboxylic acid or a
diamine. The distance between and the relative orientation of
monomers within the compounds can also be altered by replacing the
amide bond with a surrogate having additional atoms. Thus,
replacing a carbonyl group with a dicarbonyl alters the distance
between the monomers and the propensity of dicarbonyl unit to adopt
an anti arrangement of the two carbonyl moiety and alter the
periodicity of the compound. Pyromellitic anhydride represents
still another alternative to simple amide linkages which can alter
the conformation and physical properties of the compound. Modern
methods of solid phase organic chemistry (E. Atherton and R. C.
Sheppard, Solid Phase Peptide Synthesis A Practical Approach IRL
Press Oxford 1989) now allow the synthesis of homodisperse
compounds with molecular weights approaching 5,000 Daltons. Other
substitution patterns are equally effective.
[0163] The compounds also include derivatives referred to as
prodrugs, which can be prepared by modifying functional groups
present in the compounds in such a way that the modifications are
cleaved, either in routine manipulation or in vivo, to the parent
compounds. Examples of prodrugs include compounds as described
herein that contain one or more molecular moieties appended to a
hydroxyl, amino, sulfhydryl, or carboxyl group of the compound, and
that when administered to a patient, cleaves in vivo to form the
free hydroxyl, amino, sulfhydryl, or carboxyl group, respectively.
Examples of prodrugs include, but are not limited to, acetate,
formate and benzoate derivatives of alcohol and amine functional
groups in the compounds described herein. Preparation and use of
prodrugs is discussed in T. Higuchi et al., "Pro-drugs as Novel
Delivery Systems," Vol. 14 of A.C.S. Symposium Series, and in
Bioreversible Carriers in Drug Design, ed. Edward B. Roche,
American Pharmaceutical Association and Pergamon Press, 1987, both
of which are incorporated herein by reference in their
entireties.
[0164] Some of the compounds may be capable of adopting amphiphilic
conformations that allow for the segregation of polar and nonpolar
regions of the molecule into different spatial regions and provide
the basic for a number of uses.
[0165] Compounds containing an amine function can also form
N-oxides. A reference herein to a compound that contains an amine
function also includes the N-oxide. Where a compound contains
several amine functions, one or more than one nitrogen atom can be
oxidized to form an N-oxide. Examples of N-oxides include N-oxides
of a tertiary amine or a nitrogen atom of a nitrogen-containing
heterocycle. N-Oxides can be formed by treatment of the
corresponding amine with an oxidizing agent such as hydrogen
peroxide or a per-acid (e.g., a peroxycarboxylic acid) (see,
Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley
Interscience).
[0166] The structures depicted herein may omit one or more
necessary hydrogen atoms to complete the appropriate valency. Thus,
in some instances a carbon atom or nitrogen atom, for example, may
appear to have an open valency (i.e., a carbon atom with only two
bonds showing would implicitly also be bonded to two hydrogen
atoms; in addition, a nitrogen atom with a single bond depicted
would implicitly also be bonded to two hydrogen atoms). For
example, "--N" would be considered by one skilled in the art to be
"--NH.sub.2." Thus, in any structure depicted herein wherein a
valency is open, one or more hydrogen atoms is implicit, and is
only omitted for brevity.
[0167] The present disclosure provides compounds of Formula I:
##STR00013##
wherein:
[0168] each X is, independently, O, S, or S(.dbd.O).sub.2;
[0169] each R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
--C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each
p is, independently, 1 or 2;
[0170] each R.sup.2 is, independently, H, halo, --CF.sub.3, or
--C(CH.sub.3).sub.3;
[0171] each V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and
[0172] each R.sup.6 is H, --S--(CH.sub.2).sub.m--NH.sub.2,
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2,
--O--(CH.sub.2).sub.m--NH.sub.2, or
--O--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof, provided that the
compound is not:
##STR00014##
[0173] In some embodiments, each X is S.
[0174] In any of the above embodiments, each R.sup.1 is,
independently, --CH.sub.3, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently, H or
methyl; or each R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is 2 and
each R.sup.4 is H; or each R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each R.sup.1 is --CH.sub.3, --(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each R.sup.1 is --CH.sub.3 or --(CH.sub.2).sub.n--NH.sub.2 where
each n is 2.
[0175] In any of the above embodiments, each R.sup.2 is,
independently, H, Br, F, Cl, --CF.sub.3, or --C(CH.sub.3).sub.3; or
each R.sup.2 is, independently, Br, F, Cl, --CF.sub.3, or
--C(CH.sub.3).sub.3; or each R.sup.2 is --CF.sub.3.
[0176] In any of the above embodiments, each V.sup.2 is H and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 or 2; or each V.sup.2 is H and each V.sup.1 is,
indpendently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.2 is H and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 2.
[0177] In any of the above embodiments, each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
or each V.sup.1 is H and each V.sup.2 is, independently,
--S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each
R.sup.5 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each
R.sup.5 is --(CH.sub.2).sub.n--NH.sub.2 where each n is 2.
[0178] In any of the above embodiments, each R.sup.6 is H,
--S--(CH.sub.2).sub.m--NH.sub.2, or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 to 4; or each R.sup.6 is H,
--S--(CH.sub.2).sub.m--NH.sub.2, or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 or 2; or each R.sup.6 is H or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 or 2; or each R.sup.6 is H or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is
2.
[0179] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
--CF.sub.3, or --C(CH.sub.3).sub.3; and each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4.
[0180] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; each R.sup.2 is, independently, --CF.sub.3
or --C(CH.sub.3).sub.3; and each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2.
[0181] In some embodiments, each X is S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; each R.sup.2
is, independently, --CF.sub.3 or --C(CH.sub.3).sub.3; and each
V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each R.sup.5
is --(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2.
[0182] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H or
methyl; each R.sup.2 is, independently, halo, --CF.sub.3, or
--C(CH.sub.3).sub.3; and each V.sup.2 is H, and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0183] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where
each n is, independently, 1 or 2, and each R.sup.4 is,
independently, H or methyl; each R.sup.2 is, independently, halo;
and each V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0184] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
--CF.sub.3, or --C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0185] In some embodiments, each X is O or S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
each R.sup.2 is halo, --CF.sub.3, or --C(CH.sub.3).sub.3; and each
V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3, where
each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 3 or
4.
[0186] In some embodiments, each X is, independently, S or
S(.dbd.O).sub.2; each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently,
--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 1 or
2; each R.sup.2 is, independently, halo or --CF.sub.3; and each
V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4.
[0187] In some embodiments, each X is O or S; each R.sup.1 is
--CH.sub.3; each R.sup.2 is --CF.sub.3; each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.6 is
--S--(CH.sub.2).sub.m--NH.sub.2 or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 or 2.
[0188] In some embodiments, the compound is chosen from:
##STR00015## ##STR00016## ##STR00017## ##STR00018##
or a pharmaceutically acceptable salt thereof.
[0189] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0190] The present disclosure also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0191] The present disclosure also provides methods of preventing
or treating candidiasis (oral and/or disseminated) or an
aspergillus infection in a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
I:
##STR00019##
wherein:
[0192] each X is, independently, O, S, or S(.dbd.O).sub.2;
[0193] each R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
--C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each
p is, independently, 1 or 2;
[0194] each R.sup.2 is, independently, H, halo, --CF.sub.3, or
--C(CH.sub.3).sub.3;
[0195] each V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and
[0196] each R.sup.6 is H, --S--(CH.sub.2).sub.m--NH.sub.2,
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2,
--O--(CH.sub.2).sub.m--NH.sub.2, or
--O--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0197] In some embodiments, each X is S.
[0198] In any of the above embodiments, each R.sup.1 is,
independently, --CH.sub.3, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n, is
independently, 1 or 2, and each R.sup.4 is, independently, H or
methyl; or each R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is 2 and
each R.sup.4 is H; or each R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each R.sup.1 is --CH.sub.3, --(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each R.sup.1 is --CH.sub.3 or --(CH.sub.2).sub.n--NH.sub.2 where
each n is 2.
[0199] In any of the above embodiments, each R.sup.2 is,
independently, H, Br, F, Cl, --CF.sub.3, or --C(CH.sub.3).sub.3; or
each R.sup.2 is, independently, Br, F, Cl, --CF.sub.3, or
--C(CH.sub.3).sub.3; or each R.sup.2 is --CF.sub.3.
[0200] In any of the above embodiments, each V.sup.2 is H and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 or 2; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.2 is H and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 2.
[0201] In any of the above embodiments, each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
or each V.sup.2 is H and each V.sup.2 is, independently,
--S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each
R.sup.5 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each
R.sup.5 is --(CH.sub.2).sub.n--NH.sub.2 where each n is 2.
[0202] In any of the above embodiments, each R.sup.6 is H,
--S--(CH.sub.2).sub.m--NH.sub.2, or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 to 4; or each R.sup.6 is H,
--S--(CH.sub.2).sub.m--NH.sub.2, or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 or 2; or each R.sup.6 is H or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 or 2; or each R.sup.6 is H or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is
2.
[0203] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
--CF.sub.3, or --C(CH.sub.3).sub.3; and each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4.
[0204] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; each R.sup.2 is, independently, --CF.sub.3
or --C(CH.sub.3).sub.3; and each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2.
[0205] In some embodiments, each X is S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; each R.sup.2
is, independently, --CF.sub.3 or --C(CH.sub.3).sub.3; and each
V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each R.sup.5
is --(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2.
[0206] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H or
methyl; each R.sup.2 is, independently, halo, --CF.sub.3, or
--C(CH.sub.3).sub.3; and each V.sup.2 is H, and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0207] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where
each n is, independently, 1 or 2, and each R.sup.4 is,
independently, H or methyl; each R.sup.2 is, independently, halo;
and each V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0208] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
--CF.sub.3, or --C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0209] In some embodiments, each X is O or S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
each R.sup.2 is halo, --CF.sub.3, or --C(CH.sub.3).sub.3; and each
V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3, where
each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 3 or
4.
[0210] In some embodiments, each X is, independently, S or
S(.dbd.O).sub.2; each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently,
--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 1 or
2; each R.sup.2 is, independently, halo or --CF.sub.3; and each
V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4.
[0211] In some embodiments, each X is O or S; each R.sup.1 is
--CH.sub.3; each R.sup.2 is --CF.sub.3; each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.6 is
--S--(CH.sub.2).sub.m--NH.sub.2 or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 or 2.
[0212] In some embodiments, the compound is chosen from:
##STR00020## ##STR00021## ##STR00022## ##STR00023##
or a pharmaceutically acceptable salt thereof.
[0213] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula I:
##STR00024##
wherein:
[0214] each X is, independently, O, S, or S(.dbd.O).sub.2;
[0215] each R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
--C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each
p is, independently, 1 or 2;
[0216] each R.sup.2 is, independently, H, halo, --CF.sub.3, or
--C(CH.sub.3).sub.3;
[0217] each V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and
[0218] each R.sup.6 is H, --S--(CH.sub.2).sub.m--NH.sub.2,
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2,
--O--(CH.sub.2).sub.m--NH.sub.2, or
--O--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0219] In some embodiments, each X is S.
[0220] In any of the above embodiments, each R.sup.1 is,
independently, --CH.sub.3, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently, H or
methyl; or each R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is 2 and
each R.sup.4 is H; or each R.sup.1 is, independently, --CH.sub.3,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each R.sup.1 is --CH.sub.3, --(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each R.sup.1 is --CH.sub.3 or --(CH.sub.2).sub.n--NH.sub.2 where
each n is 2.
[0221] In any of the above embodiments, each R.sup.2 is,
independently, H, Br, F, Cl, --CF.sub.3, or --C(CH.sub.3).sub.3; or
each R.sup.2 is, independently, Br, F, Cl, --CF.sub.3, or
--C(CH.sub.3).sub.3; or each R.sup.2 is --CF.sub.3.
[0222] In any of the above embodiments, each V.sup.2 is H and each
V.sup.1 is, independently, --N--C(.dbd.)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 or 2; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.2 is H and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 2.
[0223] In any of the above embodiments, each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
or each V.sup.1 is H and each V.sup.2 is, independently,
--S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each
R.sup.5 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each
R.sup.5 is --(CH.sub.2).sub.n--NH.sub.2 where each n is 2.
[0224] In any of the above embodiments, each R.sup.6 is H,
--S--(CH.sub.2).sub.m--NH.sub.2, or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 to 4; or each R.sup.6 is H,
--S--(CH.sub.2).sub.m--NH.sub.2, or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 or 2; or each R.sup.6 is H or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 or 2; or each R.sup.6 is H or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is
2.
[0225] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4.
[0226] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; each R.sup.2 is, independently, --CF.sub.3
or --C(CH.sub.3).sub.3; and each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2.
[0227] In some embodiments, each X is S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; each R.sup.2
is, independently, --CF.sub.3 or --C(CH.sub.3).sub.3; and each
V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each R.sup.5
is --(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2.
[0228] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H or
methyl; each R.sup.2 is, independently, halo, --CF.sub.3, or
--C(CH.sub.3).sub.3; and each V.sup.2 is H, and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0229] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where
each n is, independently, 1 or 2, and each R.sup.4 is,
independently, H or methyl; each R.sup.2 is, independently, halo;
and each V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0230] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
--CF.sub.3, or --C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0231] In some embodiments, each X is O or S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
each R.sup.2 is halo, --CF.sub.3, or --C(CH.sub.3).sub.3; and each
V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3, where
each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 3 or
4.
[0232] In some embodiments, each X is, independently, S or
S(.dbd.O).sub.2; each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently,
--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 1 or
2; each R.sup.2 is, independently, halo or --CF.sub.3; and each
V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4.
[0233] In some embodiments, each X is O or S; each R.sup.1 is
--CH.sub.3; each R.sup.2 is --CF.sub.3; each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.6 is
--S--(CH.sub.2).sub.m--NH.sub.2 or
--S--(CH.sub.2).sub.m--NH--C(.dbd.NH)NH.sub.2, where each m is,
independently, 1 or 2.
[0234] In some embodiments, the compound is chosen from:
##STR00025## ##STR00026## ##STR00027## ##STR00028##
or a pharmaceutically acceptable salt thereof.
[0235] The present disclosure also provides compounds of Formula
II:
##STR00029##
wherein:
[0236] R.sub.1 is H;
[0237] R.sub.2 is --NH.sub.2;
[0238] R.sup.11 is, independently, --(CH.sub.2).sub.0-4--R.sup.4
where R.sup.4 is chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, --C.sub.3-C.sub.8cycloalkyl,
phenyl optionally substituted with one ore more
--C.sub.1-C.sub.4alkyl groups, --C.sub.1-C.sub.4alkoxy groups, or
halo groups, and heteroaryl optionally substituted with one or more
--C.sub.1-C.sub.4alkyl groups, --C.sub.1-C.sub.4alkoxy groups, or
halo groups;
[0239] each R.sub.9 is, independently, hydroxyethoxymethyl,
methoxyethoxymethyl, polyoxyethylene, or --(CH.sub.2).sub.q--V
where q is from 1 to 5, and each V is, independently, chosen from
amino, hydroxyl, --C.sub.1-C.sub.6alkylurea,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine, phenyl optionally substituted with an amino,
--C.sub.1-C.sub.6alkylamino, or --C.sub.1-C.sub.6dialkylamino, and
lower acylamino optionally substituted with one or more amino,
lower alkylamino, or lower dialkylamino, where the alkylene chain
is optionally substituted with an amino or hydroxyl group; and
[0240] m is 2 to at least about 30;
or a pharmaceutically acceptable salt thereof.
[0241] In some embodiments, each R.sup.11 is, independently,
--(CH.sub.2).sub.0-4--R.sup.4 where R.sup.4 is chosen from
hydrogen, --C.sub.1-C.sub.4alkyl, --C.sub.3-C.sub.12branched alkyl,
and --C.sub.3-C.sub.8cycloalkyl; or each R.sup.11 is,
independently, --(CH.sub.2).sub.1-3--R.sup.4 where R.sup.4 is
chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, and --C.sub.3-C.sub.8cycloalkyl;
or each R.sup.11 is, independently, --(CH.sub.2).sub.1-2--R.sup.4
where R.sup.4 is chosen from hydrogen or --C.sub.1-C.sub.4alkyl; or
each R.sup.11 is chosen from methyl, ethyl, n-propyl, iso-propyl,
n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl,
sec-pentyl, and benzyl.
[0242] In any of the above embodiments, each R.sub.9 is,
independently, --(CH.sub.2).sub.q--V where q is from 1 to 5, and
each V is, independently, chosen from amino, hydroxyl,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--C.sub.1-C.sub.3alkylurea, --NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine; or each R.sub.9 is, independently,
--(CH.sub.2).sub.q--V where q is from 1 to 4, and each V is,
independently, chosen from amino, hydroxyl,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--C.sub.1-C.sub.2alkylurea, --NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, and guanidine; or
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 4, and each V is, independently, chosen from amino,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--C.sub.1-C.sub.2alkylurea, amidine, and guanidine; or or each
R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is from 1
to 4, and each V is, independently, chosen from amino, amidine,
--C.sub.1-C.sub.2alkylurea, and guanidine.
[0243] In any of the above embodiments, m is 2 to at least about
20; or m is 2 to at least about 10; or m is 2 to at least about 8;
or m is 3 to at least about 6; or m is 4 to at least about 5; or m
is 5.
[0244] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is, independently, --(CH.sub.2).sub.0-4--R.sup.4
where R.sup.4 is chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, and --C.sub.3-C.sub.8cycloalkyl;
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 5, and each V is, independently, chosen from amino,
hydroxyl, --C.sub.1-C.sub.6alkylamino,
--C.sub.1-C.sub.6dialkylamino, --C.sub.1-C.sub.3alkylurea,
--NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine; and m is 2 to at least about 20.
[0245] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is, independently, --(CH.sub.2).sub.1-3--R.sup.4
where R.sup.4 is chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, and --C.sub.3-C.sub.8cycloalkyl;
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 4, and each V is, independently, chosen from amino,
hydroxyl, --C.sub.1-C.sub.6alkylamino,
--C.sub.1-C.sub.6dialkylamino, --NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine,
--C.sub.1-C.sub.2alkylurea, and guanidine; and m is 2 to at least
about 10.
[0246] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is, independently, --(CH.sub.2).sub.1-2--R.sup.4
where R.sup.4 is chosen from hydrogen or --C.sub.1-C.sub.4alkyl;
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 4, and each V is, independently, chosen from amino,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
amidine, and --C.sub.1-C.sub.2alkylurea, guanidine; and m is 3 to
at least about 6.
[0247] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is chosen from methyl, ethyl, n-propyl, iso-propyl,
n-butyl iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl,
sec-pentyl, and benzyl; each R.sub.9 is, independently,
--(CH.sub.2).sub.q--V where q is from 1 to 4, and each V is
independently, chosen from amino, amidine,
--C.sub.1-C.sub.2alkylurea, and guanidine; and m is 4 to 5.
[0248] In some embodiments, the compound is chosen from:
##STR00030##
or a pharmaceutically acceptable salt thereof.
[0249] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0250] The present disclosure also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0251] The present disclosure also provides methods of preventing
or treating candidiasis (oral and/or disseminated) or an
aspergillus infection in a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
II:
##STR00031##
wherein.
[0252] R.sub.1 is H;
[0253] R.sub.2 is --NH.sub.2;
[0254] each R.sup.11 is, independently,
--(CH.sub.2).sub.0-4--R.sup.4 where R.sup.4 is chosen from
hydrogen, --C.sub.1-C.sub.4alkyl, --C.sub.3-C.sub.12branched alkyl,
--C.sub.3-C.sub.8cycloalkyl, phenyl optionally substituted with one
or more --C.sub.1-C.sub.4alkyl groups, --C.sub.1-C.sub.4alkoxy
groups, or halo groups, and heteroaryl optionally substituted with
one or more --C.sub.1-C.sub.4alkyl groups, --C.sub.1-C.sub.4alkoxy
groups, or halo groups;
[0255] each R.sub.9 is, independently, hydroxyethoxymethyl,
methoxyethoxymethyl, polyoxyethylene, or --(CH.sub.2).sub.q--V
where q is from 1 to 5, and each V is, independently, chosen from
amino, hydroxyl, --C.sub.1-C.sub.6alkylurea,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine, phenyl optionally substituted with an amino,
--C.sub.1-C.sub.6alkylamino, or --C.sub.1-C.sub.6dialkylamino, and
lower acylamino optionally substituted with one or more amino,
lower alkylamino, or lower dialkylamino, where the alkylene chain
is optionally substituted with an amino or hydroxyl group; and
[0256] m is 2 to at least about 30;
or a pharmaceutically acceptable salt thereof.
[0257] In some embodiments, each R.sup.11 is, independently,
--(CH.sub.2).sub.0-4--R.sup.4 where R.sup.4 is chosen from
hydrogen, --C.sub.1-C.sub.4alkyl, --C.sub.3-C.sub.12branched alkyl,
and --C.sub.3-C.sub.8cycloalkyl; or each R.sup.11 is,
independently, --(CH.sub.2).sub.1-3--R.sup.4 where R.sup.4 is
chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, and --C.sub.3-C.sub.8cycloalkyl;
or each R.sup.11 is, independently, --(CH.sub.2).sub.1-2--R.sup.4
where R.sup.4 is chosen from hydrogen or --C.sub.1-C.sub.4alkyl; or
each R.sup.11 is chosen from methyl, ethyl, n-propyl, iso-propyl,
n-butyl iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl,
sec-pentyl, and benzyl.
[0258] In any of the above embodiments, each R.sub.9 is,
independently, --(CH.sub.2).sub.q--V where q is from 1 to 5, and
each V is, independently, chosen from amino, hydroxyl,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--C.sub.1-C.sub.3alkylurea, --NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine; or each R.sub.9 is, independently,
--(CH.sub.2).sub.q--V where q is from 1 to 4, and each V is,
independently, chosen from amino, hydroxyl,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--C.sub.1-C.sub.2-alkylurea, --NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, and guanidine; or
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 4, and each V is, independently, chosen from amino,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--C.sub.1-C.sub.2alkylurea, amidine, and guanidine; or or each
R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is from 1
to 4, and each V is, independently, chosen from amino, amidine,
--C.sub.1-C.sub.2alkylurea, and guanidine.
[0259] In any of the above embodiments, m is 2 to at least about
20; or m is 2 to at least about 10; or m is 2 to at least about 8;
or m is 3 to at least about 6; or m is 4 to at least about 5; or m
is 5.
[0260] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is, independently, --(CH.sub.2).sub.0-4--R.sup.4
where R.sup.4 is chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, and --C.sub.3-C.sub.8cycloalkyl;
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 5, and each V is, independently, chosen from amino,
hydroxyl, --C.sub.1-C.sub.6alkylamino,
--C.sub.1-C.sub.6dialkylamino, --C.sub.1-C.sub.3alkylurea,
--NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine; and m is 2 to at least about 20.
[0261] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is, independently, --(CH.sub.2).sub.1-3--R.sup.4
where R.sup.4 is chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, and --C.sub.3-C.sub.8cycloalkyl;
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 4, and each V is, independently, chosen from amino,
hydroxyl, --C.sub.1-C.sub.6alkylamino,
--C.sub.1-C.sub.6dialkylamino, --NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine,
--C.sub.1-C.sub.2-alkylurea, and guanidine; and m is 2 to at least
about 10.
[0262] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is, independently, --(CH.sub.2).sub.1-2--R.sup.4
where R.sup.4 is chosen from hydrogen or --C.sub.1-C.sub.4alkyl;
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 4, and each V is, independently, chosen from amino,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
amidine, and --C.sub.1-C.sub.2alkylurea, guanidine; and m is 3 to
at least about 6.
[0263] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is chosen from methyl, ethyl, n-propyl, iso-propyl,
n-butyl iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl,
sec-pentyl, and benzyl; each R.sub.9 is, independently,
--(CH.sub.2).sub.q--V where q is from 1 to 4, and each V is,
independently, chosen from amino, amidine,
--C.sub.1-C.sub.2alkylurea, and guanidine; and m is 4 to 5.
[0264] In some embodiments, the compound is chosen from:
##STR00032##
or a pharmaceutically acceptable salt thereof.
[0265] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula II:
##STR00033##
wherein:
[0266] R.sub.1 is H;
[0267] R.sub.2 is --NH.sub.2;
[0268] each R.sup.11 is, independently,
--(CH.sub.2).sub.0-4--R.sup.4 where R.sup.4 is chosen from
hydrogen, --C.sub.1-C.sub.4alkyl, --C.sub.3-C.sub.12branched alkyl,
--C.sub.3-C.sub.8cycloalkyl, phenyl optionally substituted with one
or more --C.sub.1-C.sub.4alkyl groups, --C.sub.1-C.sub.4alkoxy
groups, or halo groups, and heteroaryl optionally substituted with
one or more --C.sub.1-C.sub.4alkyl groups, --C.sub.1-C.sub.4alkoxy
groups, or halo groups;
[0269] each R.sub.9 is, independently, hydroxyethoxymethyl,
methoxyethoxymethyl, polyoxyethylene, or --(CH.sub.2).sub.q--V
where q is from 1 to 5, and each V is, independently, chosen from
amino, hydroxyl, --C.sub.1-C.sub.6alkylurea,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine, phenyl optionally substituted with an amino,
--C.sub.1-C.sub.6alkylamino, or --C.sub.1-C.sub.6dialkylamino, and
lower acylamino optionally substituted with one or more amino,
lower alkylamino, or lower dialkylamino, where the alkylene chain
is optionally substituted with an amino or hydroxyl group; and
[0270] m is 2 to at least about 30;
or a pharmaceutically acceptable salt thereof.
[0271] In some embodiments, each R.sup.11 is, independently,
--(CH.sub.2).sub.0-4--R.sup.4 where R.sup.4 is chosen from
hydrogen, --C.sub.1-C.sub.4alkyl, --C.sub.3-C.sub.12branched alkyl,
and --C.sub.3-C.sub.8cycloalkyl; or each R.sup.11 is,
independently, --(CH.sub.2).sub.1-3--R.sup.4 where R.sup.4 is
chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, and --C.sub.3-C.sub.8cycloalkyl;
or each R.sup.11 is, independently, --(CH.sub.2).sub.1-2--R.sup.4
where R.sup.4 is chosen from hydrogen or --C.sub.1-C.sub.4alkyl; or
each R.sup.11 is chosen from methyl, ethyl, n-propyl, iso-propyl,
n-butyl iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl,
sec-pentyl, and benzyl.
[0272] In any of the above embodiments, each R.sub.9 is,
independently, --(CH.sub.2).sub.q--V where q is from 1 to 5, and
each V is, independently, chosen from amino, hydroxyl,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--C.sub.1-C.sub.3alkylurea, --NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine; or each R.sub.9 is, independently,
--(CH.sub.2).sub.q--V where q is from 1 to 4, and each V is,
independently, chosen from amino, hydroxyl,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--C.sub.1-C.sub.2alkylurea, --NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, and guanidine; or
each R.sup.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 4, and each V is, independently, chosen from amino,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
--C.sub.1-C.sub.2alkylurea, amidine, and guanidine; or or each
R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is from 1
to 4, and each V is, independently, chosen from amino, amidine,
--C.sub.1-C.sub.2alkylurea, and guanidine.
[0273] In any of the above embodiments, m is 2 to at least about
20; or m is 2 to at least about 10; or m is 2 to at least about 8;
or m is 3 to at least about 6; or m is 4 to at least about 5; or m
is or 5.
[0274] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is, independently, --(CH.sub.2).sub.0-4--R.sup.4
where R.sup.4 is chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, and --C.sub.3-C.sub.8cycloalkyl;
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 5, and each V is, independently, chosen from amino,
hydroxyl, --C.sub.1-C.sub.6alkylamino,
--C.sub.1-C.sub.6dialkylamino, --C.sub.1-C.sub.3alkylurea,
--NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine, guanidine,
semicarbazone, imidazole, piperidine, piperazine,
4-alkylpiperazine; and m is 2 to at least about 20.
[0275] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is, independently, --(CH.sub.2).sub.1-3--R.sup.4
where R.sup.4 is chosen from hydrogen, --C.sub.1-C.sub.4alkyl,
--C.sub.3-C.sub.12branched alkyl, and --C.sub.3-C.sub.8cycloalkyl;
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 4, and each V is, independently, chosen from amino,
hydroxyl, --C.sub.1-C.sub.6alkylamino,
--C.sub.1-C.sub.6dialkylamino, --NH(CH.sub.2).sub.1-4NH.sub.2,
--N(CH.sub.2CH.sub.2NH.sub.2).sub.2, amidine,
--C.sub.1-C.sub.2alkylurea, and guanidine; and m is 2 to at least
about 10.
[0276] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is, independently, --(CH.sub.2).sub.1-2--R.sup.4
where R.sup.4 is chosen from hydrogen or --C.sub.1-C.sub.4alkyl;
each R.sub.9 is, independently, --(CH.sub.2).sub.q--V where q is
from 1 to 4, and each V is, independently, chosen from amino,
--C.sub.1-C.sub.6alkylamino, --C.sub.1-C.sub.6dialkylamino,
amidine, and --C.sub.1-C.sub.2alkylurea, guanidine; and m is 3 to
at least about 6.
[0277] In some embodiments, R.sub.1 is H; R.sub.2 is --NH.sub.2;
each R.sup.11 is chosen from methyl, ethyl, n-propyl, iso-propyl,
n-butyl iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl,
sec-pentyl, and benzyl; each R.sub.9 is, independently,
--(CH.sub.2).sub.q--V where q is from 1 to 4, and each V is,
independently, chosen from amino, amidine,
--C.sub.1-C.sub.2alkylurea, and guanidine; and m is 4 to 5.
[0278] In some embodiments, the compound is chosen from:
##STR00034##
or a pharmaceutically acceptable salt thereof.
[0279] The present disclosure also provides compounds of Formula
III:
##STR00035##
wherein:
[0280] X is --C(R.sup.7)C(R.sup.8), --C(.dbd.O), --N(R.sup.9), O,
S, S(.dbd.O), or S(.dbd.O).sub.2;
[0281] R.sup.7, R.sup.8, and R.sup.9 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, --OH,
--CF.sub.3, aromatic group, --(CH.sub.2).sub.qNH.sub.2, or
--(CH.sub.2).sub.qNHC(.dbd.NH)NH.sub.2, where q is 0 to 4;
[0282] R.sup.1 and R.sup.2 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, --OH,
-haloC.sub.1-C.sub.8alkyl, --CN, or --CF.sub.3;
[0283] R.sup.3 and R.sup.4 are, independently, H or
-carbocycle(R.sup.5)(R.sup.6);
[0284] each R.sup.5 and each R.sup.6 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, amino, --OH,
--CF.sub.3, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, aromatic group, heterocycle, or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8;
[0285] provided that the compound is not Compound 116-134;
or a pharmaceutically acceptable salt thereof.
[0286] In some embodiments, X is --N(R.sup.9), O, S, or
S(.dbd.O).sub.2; or X is --NH, O, S, or
--N(CH.sub.2).sub.qNH.sub.2, where q is 2 or 3; or X is --NH,
--N(CH.sub.2).sub.3NH.sub.2, or S.
[0287] In any of the above embodiments, R.sup.1 and R.sup.2 are,
independently, H, --C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy,
halo, --OH, -haloC.sub.1-C.sub.3alkyl, or --CN; or R.sup.1 and
R.sup.2 are, independently, H, --C.sub.1-C.sub.3alkyl,
--C.sub.1-C.sub.3alkoxy, halo, or --OH; or R.sup.1 and R.sup.2 are,
independently, H, --C.sub.1-C.sub.3alkyl, or halo; or R.sup.1 and
R.sup.2 are H.
[0288] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently, H or -carbocycle(R.sup.5)(R.sup.6), where R.sup.5
and R.sup.6 can be positioned anywhere on the carbocycle. In any of
the above embodiments, R.sup.3 and R.sup.4 are, independently,
##STR00036##
wherein each W, Y, and Z are, independently, C or N, each A, D, and
Q are, independently, --C(R.sup.10)C(R.sup.11), --C(.dbd.O),
--N(R.sup.12), O, or S, and each R.sup.10, R.sup.11, and R.sup.12
are, independently, H, --C.sub.1-C.sub.8alkyl,
--C.sub.1-C.sub.8alkoxy, halo, --OH, --CF.sub.3, or aromatic
group.
[0289] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently,
##STR00037##
wherein each W, Y, and Z are, independently, C or N; or R.sup.3 and
R.sup.4 are, independently,
##STR00038##
wherein each W, Y, and Z are C, or each Y and Z are C and each W is
N.
[0290] In any of the above embodiments, each R.sup.5 is,
independently, H, --C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy,
halo, amino, --OH, --CF.sub.3, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, or the free base of salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8, and each R.sup.6 is, independently, amino,
heterocycle, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8; or each R.sup.5 is, independently, H,
--C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy, halo, --OH,
--CF.sub.3, or --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 1 to 5, and each R.sup.6 is, independently,
heterocycle, --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 1 to 5, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
8; or each R.sup.5 is, independently, H, --C.sub.1-C.sub.3alkyl,
halo, --OH, or --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 2 or 3, and each R.sup.6 is, independently,
heterocycle, --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 2 or 3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.5 is, independently, H, --C.sub.1-C.sub.3alkyl,
halo, --OH, or --O--(CH.sub.2).sub.3--NH.sub.2, and each R.sup.6
is, independently, 6-membered heterocycle,
--O--(CH.sub.2).sub.3--NH.sub.2, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is, independently, H, halo, or
--O--(CH.sub.2).sub.3--NH.sub.2, and each R.sup.6 is piperazinyl,
--O--(CH.sub.2).sub.3--NH.sub.2, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 where each n is, independently, 1 to
3; or each R.sup.5 is --O--(CH.sub.2).sub.3--NH.sub.2 or
piperazinyl, and each R.sup.6 is, independently, H,
--C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy, halo, --OH,
--CF.sub.3, or --O--(CH.sub.2).sub.3--NH.sub.2, or each R.sup.5 is
piperazinyl or --O--(CH.sub.2).sub.3--NH.sub.2; and each R.sup.6 is
H, --C.sub.1-C.sub.3alkyl, halo, --OH, --CF.sub.3, or
--O--(CH.sub.2).sub.3--NH.sub.2.
[0291] In some embodiments, X is --NH, O, S, S(.dbd.O).sub.2, or
--N(CH.sub.2).sub.2-3NH.sub.2; R.sup.1 and R.sup.2 are H; R.sup.3
and R.sup.4 are, independently,
##STR00039##
wherein: each W, Y, and Z are, independently, C or N; each R.sup.5
and each R.sup.6 are, independently, H, heterocycle,
--O--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 1
to 3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3.
[0292] In some embodiments, X is --NH, O, S, or
--N(CH.sub.2).sub.2-3NH.sub.2; R.sup.1 and R.sup.2 are H; R.sup.3
and R.sup.4 are
##STR00040##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is, independently, H, amino, halo, or
--O--(CH.sub.2).sub.p--NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 2 or 3, and each R.sup.6 is piperazinyl, amino,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2,
--O--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 2
or 3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is piperazinyl or
--O--(CH.sub.2).sub.3--NH.sub.2, and each R.sup.6 is,
independently, H, --C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy,
halo, --OH, --CF.sub.3, or --O--(CH.sub.2).sub.3--NH.sub.2.
[0293] In some embodiments, X is --NH, O, S, or
--N(CH.sub.2).sub.2-3NH.sub.2; R.sup.1 and R.sup.2 are H; R.sup.3
and R.sup.4 are
##STR00041##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is H or --O--(CH.sub.2).sub.3--NH.sub.2, and each
R.sup.6 is piperazinyl, --O--(CH.sub.2).sub.3--NH.sub.2, or the
free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each
n is, independently, 1 to 3; or each R.sup.5 is piperazinyl or
--O--(CH.sub.2).sub.3--NH.sub.2; and each R.sup.6 is H or
--O--(CH.sub.2).sub.3--NH.sub.2.
[0294] In some embodiments, the compound is chosen from:
##STR00042## ##STR00043## ##STR00044## ##STR00045## ##STR00046##
##STR00047## ##STR00048## ##STR00049## ##STR00050##
or a pharmaceutically acceptable salt thereof.
[0295] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0296] The present disclosure also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0297] The present disclosure also provides methods of preventing
or treating candidiasis (oral and/or disseminated) or an
aspergillus infection in a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
III:
##STR00051##
wherein:
[0298] X is --C(R.sup.7)C(R.sup.8), --C(.dbd.O), N(R.sup.9), O, S,
S(.dbd.O), or S(.dbd.O).sub.2;
[0299] R.sup.7, R.sup.8, and R.sup.9 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, --OH,
--CF.sub.3, aromatic group, --(CH.sub.2).sub.qNH.sub.2, or
--(CH.sub.2).sub.qNHC(.dbd.NH)NH.sub.2, where q is 0 to 4;
[0300] R.sup.1 and R.sup.2 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, --OH,
-haloC.sub.1-C.sub.8alkyl, --CN, or --CF.sub.3;
[0301] R.sup.3 and R.sup.4 are, independently, H or -carbocycle
(R.sup.5)(R.sup.6);
[0302] each R.sup.5 and R.sup.6 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, amino, --OH,
--CF.sub.3, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, aromatic group, heterocycle, or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8;
or a pharmaceutically acceptable salt thereof.
[0303] In some embodiments, X is --N(R.sup.9), O, S, or
S(.dbd.O).sub.2; or X is --NH, O, S, or
--N(CH.sub.2).sub.qNH.sub.2, where q is 2 or 3; or X is --NH,
--N(CH.sub.2).sub.3NH.sub.2, or S.
[0304] In any of the above embodiments, R.sup.1 and R.sup.2 are,
independently, H, --C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy,
halo, --OH, -haloC.sub.1-C.sub.3alkyl, or --CN; or R.sup.1 and
R.sup.2 are, independently, H, --C.sub.1-C.sub.3alkyl,
--C.sub.1-C.sub.3alkoxy, halo, or --OH; or R.sup.1 and R.sup.2 are,
independently, H, --C.sub.1-C.sub.3alkyl, or halo; or R.sup.1 and
R.sup.2 are H.
[0305] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently, H or -carbocycle(R.sup.5)R.sup.6), where R.sup.5 and
R.sup.6 can be positioned anywhere on the carbocycle. In any of the
above embodiments, R.sup.3 and R.sup.4 are, independently,
##STR00052##
wherein each W, Y, and Z are, independently, C or N, each A, D, and
Q are, independently, --C(R.sup.10)C(R.sup.11), --C(.dbd.O),
--N(R.sup.12), O, or S, and each R.sup.10, R.sup.11, and R.sup.12
are, independently, H, --C.sub.1-C.sub.8alkyl,
--C.sub.1-C.sub.8alkoxy, halo, --OH, --CF.sub.3, or aromatic
group.
[0306] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently,
##STR00053##
wherein each W, Y, and Z are, independently, C or N; or R.sup.3 and
R.sup.4 are, independently,
##STR00054##
wherein each W, Y, and Z are C, or each Y and Z are C and each W is
N.
[0307] In any of the above embodiments, each R.sup.5 is,
independently, H, --C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy,
halo, amino, --OH, --CF.sub.3, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8, and each R.sup.6 is, independently,
heterocycle, amino, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8; or each R.sup.5 is, independently, H,
--C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy, halo, --OH,
--CF.sub.3, or --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 1 to 5, and each R.sup.6 is, independently,
heterocycle, --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 1 to 5, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
8; or each R.sup.5 is, independently, H, --C.sub.1-C.sub.3alkyl,
halo, --OH, or --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 2 or 3, and each R.sup.6 is, independently,
heterocycle, --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 2 or 3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.5 is, independently, H, --C.sub.1-C.sub.3alkyl,
halo, --OH, or --O--(CH.sub.2).sub.3--NH.sub.2, and each R.sup.6
is, independently, 6-membered heterocycle,
--O--(CH.sub.2).sub.3--NH.sub.2, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is, independently, H, halo, or
--O--(CH.sub.2).sub.3--NH.sub.2, and each R.sup.6 is piperazinyl,
--O--(CH.sub.2).sub.3--NH.sub.2, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 where each n is, independently, 1 to
3; or each R.sup.5 is --O--(CH.sub.2).sub.3--NH.sub.2 or
piperazinyl, and each R.sup.6 is, independently, H,
--C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy, halo, --OH,
--CF.sub.3, or --O--(CH.sub.2).sub.3--NH.sub.2, or each R.sup.5 is
piperazinyl or --O--(CH.sub.2).sub.3--NH.sub.2; and each R.sup.6 is
H, --C.sub.1-C.sub.3alkyl, halo, --OH, --CF.sub.3, or
--O--(CH.sub.2).sub.3--NH.sub.2.
[0308] In some embodiments, X is --NH, O, S, S(.dbd.O).sub.2, or
--N(CH.sub.2).sub.2-3NH.sub.2; R.sup.1 and R.sup.2 are H; R.sup.3
and R.sup.4 are, independently,
##STR00055##
wherein: each W, Y, and Z are, independently, C or N; each R.sup.5
and each R.sup.6 are, independently, H, heterocycle,
--O--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 1
to 3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3.
[0309] In some embodiments, X is --NH, O, S, or
--N(CH.sub.2).sub.2-3NH.sub.2; R.sup.1 and R.sup.2 are H; R.sup.3
and R.sup.4 are
##STR00056##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is, independently, H, halo, amino, or
--O--(CH.sub.2).sub.p--NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 2 or 3, and each R.sup.6 is piperazinyl, amino,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2,
--O--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 2
or 3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is piperazinyl or
--O--(CH.sub.2).sub.3--NH.sub.2, and each R.sup.6 is,
independently, H, --C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy,
halo, --OH, --CF.sub.3, or --O--(CH.sub.2).sub.3--NH.sub.2.
[0310] In some embodiments, X is --NH, O, S, or
--N(CH.sub.2).sub.2-3NH.sub.2; R.sup.1 and R.sup.2 are H; R.sup.3
and R.sup.4 are
##STR00057##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is H or --O--(CH.sub.2).sub.3--NH.sub.2, and each
R.sup.6 is piperazinyl, --O--(CH.sub.2).sub.3--NH.sub.2, or the
free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each
n is, independently, 1 to 3; or each R.sup.5 is piperazinyl or
--O--(CH.sub.2).sub.3--NH.sub.2; and each R.sup.6 is H or
--O--(CH.sub.2).sub.3--NH.sub.2.
[0311] In some embodiments, the compound is chosen from:
##STR00058## ##STR00059## ##STR00060## ##STR00061## ##STR00062##
##STR00063## ##STR00064## ##STR00065##
or a pharmaceutically acceptable salt thereof.
[0312] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula III:
##STR00066##
wherein:
[0313] X is --C(R.sup.7)C(R.sup.8), --C(.dbd.O), --N(R.sup.9), O,
S, S(.dbd.O), or S(.dbd.O).sub.2;
[0314] R.sup.7, R.sup.8, and R.sup.9 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, --OH,
--CF.sub.3, aromatic group, --(CH.sub.2).sub.qNH.sub.2, or
--(CH.sub.2).sub.qNHC(.dbd.NH)NH.sub.2, where q is 0 to 4;
[0315] R.sup.1 and R.sup.2 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, --OH,
-haloC.sub.1-C.sub.8alkyl, --CN, or --CF.sub.3;
[0316] R.sup.3 and R.sup.4 are, independently, H or
-carbocycle(R.sup.5)(R.sup.6);
[0317] each R.sup.5 and each R.sup.6 are, independently, H,
--C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy, halo, amino, --OH,
--CF.sub.3, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, aromatic group, heterocycle, or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8;
or a pharmaceutically acceptable salt thereof.
[0318] In some embodiments, X is --N(R.sup.9), O, S, or
S(.dbd.O).sub.2; or X is --NH, O, S, or
--N(CH.sub.2).sub.qNH.sub.2, where q is 2 or 3; or X is --NH,
--N(CH.sub.2).sub.3NH.sub.2, or S.
[0319] In any of the above embodiments, R.sup.1 and R.sup.2 are,
independently, H, --C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy,
halo, --OH, -haloC.sub.1-C.sub.3alkyl, or --CN; or R.sup.1 and
R.sup.2 are, independently, H, --C.sub.1-C.sub.3alkyl,
--C.sub.1-C.sub.3alkoxy, halo, or --OH; or R.sup.1 and R.sup.2 are,
independently, H, --C.sub.1-C.sub.3alkyl, or halo; or R.sup.1 and
R.sup.2 are H.
[0320] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently, H or -carbocycle(R.sup.5)(R.sup.6), where R.sup.5
and R.sup.6 can be positioned anywhere on the carbocycle. In any of
the above embodiments, R.sup.3 and R.sup.4 are, independently,
##STR00067##
wherein each W, Y, and Z are, independently, C or N, each A, D, and
Q are, independently, --C(R.sup.10)C(R.sup.11), --C(.dbd.O),
--N(R.sup.12), O, or S, and each R.sup.10, R.sup.11, and R.sup.12
are, independently, H, --C.sub.1-C.sub.8alkyl,
--C.sub.1-C.sub.8alkoxy, halo, --OH, --CF.sub.3, or aromatic
group.
[0321] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently,
##STR00068##
wherein each W, Y, and Z are, independently, C or N; or R.sup.3 and
R.sup.4 are, independently,
##STR00069##
wherein each W, Y, and Z are C, or each Y and Z are C and each W is
N.
[0322] In any of the above embodiments, each R.sup.5 is,
independently, H, --C.sub.1-C.sub.8alkyl, --C.sub.1-C.sub.8alkoxy,
halo, amino, --OH, --CF.sub.3, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8, and each R.sup.6 is, independently,
heterocycle, amino, --O--(CH.sub.2).sub.p--NH.sub.2,
--O--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--S--(CH.sub.2).sub.p--NH.sub.2,
--S--(CH.sub.2).sub.pNHC(.dbd.NH)NH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 1 to 5, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8; or each R.sup.5 is, independently, H,
--C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy, halo, --OH,
--CF.sub.3, or --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 1 to 5, and each R.sup.6 is, independently,
heterocycle, --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 1 to 5, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
8; or each R.sup.5 is, independently, H, --C.sub.1-C.sub.3alkyl,
halo, --OH, or --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 2 or 3, and each R.sup.6 is, independently,
heterocycle, --O--(CH.sub.2).sub.p--NH.sub.2, where each p is,
independently, 2 or 3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.5 is, independently, H, --C.sub.1-C.sub.3alkyl,
halo, --OH, or --O--(CH.sub.2).sub.3--NH.sub.2, and each R.sup.6
is, independently, 6-membered heterocycle,
--O--(CH.sub.2).sub.3--NH.sub.2, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is, independently, H, halo, or
--O--(CH.sub.2).sub.3--NH.sub.2, and each R.sup.6 is piperazinyl,
--O--(CH.sub.2).sub.3--NH.sub.2, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 where each n is, independently, 1 to
3; or each R.sup.5 is --O--(CH.sub.2).sub.3--NH.sub.2 or
piperazinyl, and each R.sup.6 is, independently, H,
--C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy, halo, --OH,
--CF.sub.3, or --O--(CH.sub.2).sub.3--NH.sub.2, or each R.sup.5 is
piperazinyl or --O--(CH.sub.2).sub.3--NH.sub.2; and each R.sup.6 is
H, --C.sub.1-C.sub.3alkyl, halo, --OH, --CF.sub.3, or
--O--(CH.sub.2).sub.3--NH.sub.2.
[0323] In some embodiments, X is --NH, O, S, S(.dbd.O).sub.2, or
--N(CH.sub.2).sub.2-3NH.sub.2; R.sup.1 and R.sup.2 are H; R.sup.3
and R.sup.4 are, independently,
##STR00070##
wherein: each W, Y, and Z are, independently, C or N; each R.sup.5
and each R.sup.6 are, independently, H, heterocycle,
--O--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 1
to 3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3.
[0324] In some embodiments, X is --NH, O, S, or
--N(CH.sub.2).sub.2-3NH.sub.2; R.sup.1 and R.sup.2 are H; R.sup.3
and R.sup.4 are
##STR00071##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is, independently, H, halo, or amino,
--O--(CH.sub.2).sub.p--NH.sub.2,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2, where each p
is, independently, 2 or 3, and each R.sup.6 is piperazinyl, amino,
--C(.dbd.O)NH(CH.sub.2).sub.pNH.sub.2,
--N((CH.sub.2).sub.pNH.sub.2).sub.2,
--(CH.sub.2).sub.pN((CH.sub.2).sub.pNH.sub.2).sub.2,
--O--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 2
or 3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is piperazinyl or
--O--(CH.sub.2).sub.3--NH.sub.2, and each R.sup.6 is independently,
H, --C.sub.1-C.sub.3alkyl, --C.sub.1-C.sub.3alkoxy, halo, --OH,
--CF.sub.3, or --O--(CH.sub.2).sub.3--NH.sub.2.
[0325] In some embodiments, X is --NH, O, S, or
--N(CH.sub.2).sub.2-3NH.sub.2; R.sup.1 and R.sup.2 are H; R.sup.3
and R.sup.4 are
##STR00072##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is H or --O--(CH.sub.2).sub.3--NH.sub.2, and each
R.sup.6 is piperazinyl, --O--(CH.sub.2).sub.3--NH.sub.2, or the
free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each
n is, independently, 1 to 3; or each R.sup.5 is piperazinyl or
--O--(CH.sub.2).sub.3--NH.sub.2; and each R.sup.6 is H or
--O--(CH.sub.2).sub.3--NH.sub.2.
[0326] In some embodiments, the compound is chosen from:
##STR00073## ##STR00074## ##STR00075## ##STR00076## ##STR00077##
##STR00078## ##STR00079## ##STR00080##
or a pharmaceutically acceptable salt thereof.
[0327] The present disclosure also provides compounds of Formula
IV
##STR00081##
wherein:
[0328] R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.NH)NH.sub.2, where n is 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.
[0329] In some embodiments, R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.NH)NH.sub.2, where n is 2 or 3.
[0330] In some embodiments, R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2 or --(CH.sub.2).sub.nNH.sub.2, where n is 2 or
3.
[0331] In some embodiments, the compound is
##STR00082##
or a pharmaceutically acceptable salt thereof.
[0332] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0333] The present disclosure also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0334] The present disclosure also provides methods of preventing
or treating candidiasis (oral and/or disseminated) or an
aspergillus infection in a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
IV:
##STR00083##
wherein:
[0335] R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.NH)NH.sub.2, where n is 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.
[0336] In some embodiments, R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.NH)NH.sub.2, where n is 2 or 3.
[0337] In some embodiments, R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2 or --(CH.sub.2).sub.nNH.sub.2, where n is 2 or
3.
[0338] In some embodiments, the compound is:
##STR00084##
or a pharmaceutically acceptable salt thereof.
[0339] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula IV:
##STR00085##
wherein:
[0340] R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.NH)NH.sub.2, where n is 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.
[0341] In some embodiments, R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.NH)NH.sub.2, where n is 2 or 3.
[0342] In some embodiments, R.sup.1 and R.sup.2 are, independently,
--C(.dbd.NH)NH.sub.2 or --(CH.sub.2).sub.nNH.sub.2, where n is 2 or
3.
[0343] In some embodiments, the compound is:
##STR00086##
or a pharmaceutically acceptable salt thereof.
[0344] The present disclosure also provides compounds of Formula
V:
##STR00087##
wherein:
[0345] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0346] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0347] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0348] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0349] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0350] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0351] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
or a pharmaceutically acceptable salt thereof.
[0352] In some embodiments, R.sup.1 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.1
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.1 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.1 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0353] In any of the above embodiments, R.sup.2 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.2 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0354] In any of the above embodiments, R.sup.3 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.3
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.3 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0355] In any of the above embodiments, R.sup.4 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.4 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0356] In any of the above embodiments, R.sup.5 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.5 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0357] In any of the above embodiments, R.sup.6 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.6 is H or --(CH.sub.2).sub.nNH.sub.2,
where n is 2, 3, or 4; or R.sup.6 is H or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 3 or 4.
[0358] In any of the above embodiments, R.sup.7 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.7 is H or --(CH.sub.2).sub.nNH.sub.2,
where n is 2, 3, or 4; or R.sup.7 is H or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 3 or 4.
[0359] In some embodiments:
[0360] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0361] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0362] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0363] R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0364] R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0365] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0366] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4.
[0367] In some embodiments:
[0368] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0369] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0370] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0371] R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0372] R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0373] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0374] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4.
[0375] In some embodiments:
[0376] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0377] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0378] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0379] R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0380] R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0381] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; and
[0382] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0383] In some embodiments:
[0384] R.sup.1 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0385] R.sup.2 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0386] R.sup.3 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0387] R.sup.4 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0388] R.sup.5 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0389] R.sup.6 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4; and
[0390] R.sup.7 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4.
[0391] In some embodiments:
[0392] R.sup.1 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0393] R.sup.2 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0394] R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0395] R.sup.4 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0396] R.sup.5 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0397] R.sup.6 is H or --O--(CH.sub.2).sub.nNH.sub.2, where n is 3
or 4; and
[0398] R.sup.7 is H or --O--(CH.sub.2).sub.nNH.sub.2, where n is 3
or 4.
[0399] In some embodiments, the compound is
##STR00088##
[0400] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0401] The present disclosure also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0402] The present disclosure also provides methods of preventing
or treating candidiasis (oral and/or disseminated) or an
aspergillus infection in a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
V:
##STR00089##
wherein:
[0403] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0404] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0405] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0406] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0407] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0408] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0409] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
or a pharmaceutically acceptable salt thereof.
[0410] In some embodiments, R.sup.1 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.1
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.1 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.1 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0411] In any of the above embodiments, R.sup.2 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.2 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0412] In any of the above embodiments, R.sup.3 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.3
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.3 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0413] In any of the above embodiments, R.sup.4 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.4 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0414] In any of the above embodiments, R.sup.5 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.5 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0415] In any of the above embodiments, R.sup.6 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.6 is H or --(CH.sub.2).sub.nNH.sub.2,
where n is 2, 3, or 4; or R.sup.6 is H or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 3 or 4.
[0416] In any of the above embodiments, R.sup.7 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.7 is H or --(CH.sub.2).sub.nNH.sub.2,
where n is 2, 3, or 4; or R.sup.7 is H or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 3 or 4.
[0417] In some embodiments:
[0418] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0419] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0420] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0421] R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0422] R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0423] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0424] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4.
[0425] In some embodiments:
[0426] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0427] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0428] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0429] R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0430] R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0431] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0432] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4.
[0433] In some embodiments:
[0434] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0435] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0436] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0437] R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0438] R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0439] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; and
[0440] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0441] In some embodiments:
[0442] R.sup.1 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0443] R.sup.2 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0444] R.sup.3 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0445] R.sup.4 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0446] R.sup.5 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0447] R.sup.6 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4; and
[0448] R.sup.7 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4.
[0449] In some embodiments:
[0450] R.sup.1 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0451] R.sup.2 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0452] R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0453] R.sup.4 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0454] R.sup.5 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0455] R.sup.6 is H or --O--(CH.sub.2).sub.nNH.sub.2, where n is 3
or 4; and
[0456] R.sup.7 is H or --O--(CH.sub.2).sub.nNH.sub.2, where n is 3
or 4.
[0457] In some embodiments, the compound is
##STR00090##
[0458] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula V:
##STR00091##
wherein:
[0459] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0460] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0461] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0462] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0463] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0464] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0465] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
or a pharmaceutically acceptable salt thereof.
[0466] In some embodiments, R.sup.1 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.1
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.1 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.1 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0467] In any of the above embodiments, R.sup.2 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.2 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0468] In any of the above embodiments, R.sup.3 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.3
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.3 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0469] In any of the above embodiments, R.sup.4 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.4 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0470] In any of the above embodiments, R.sup.5 is
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5
is --NH(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.5 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0471] In any of the above embodiments, R.sup.6 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2,3, or 4; or
R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.6 is H or --(CH.sub.2).sub.nNH.sub.2,
where n is 2, 3, or 4; or R.sup.6 is H or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 3 or 4.
[0472] In any of the above embodiments, R.sup.7 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.7 is H or --(CH.sub.2).sub.nNH.sub.2,
where n is 2, 3, or 4; or R.sup.7 is H or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 3 or 4.
[0473] In some embodiments:
[0474] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0475] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0476] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0477] R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0478] R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0479] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0480] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4.
[0481] In some embodiments:
[0482] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0483] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0484] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0485] R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0486] R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
or --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0487] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0488] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4.
[0489] In some embodiments:
[0490] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0491] R.sup.2 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0492] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0493] R.sup.4 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0494] R.sup.5 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4;
[0495] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; and
[0496] R.sup.7 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0497] In some embodiments:
[0498] R.sup.1 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0499] R.sup.2 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0500] R.sup.3 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0501] R.sup.4 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0502] R.sup.5 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0503] R.sup.6 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4; and
[0504] R.sup.7 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4.
[0505] In some embodiments:
[0506] R.sup.1 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0507] R.sup.2 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0508] R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0509] R.sup.4 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0510] R.sup.5 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0511] R.sup.6 is H or --O--(CH.sub.2).sub.nNH.sub.2, where n is 3
or 4; and
[0512] R.sup.7 is H or --O--(CH.sub.2).sub.nNH.sub.2, where n is 3
or 4.
[0513] In some embodiments, the compound is
##STR00092##
[0514] The present disclosure also provides compounds of Formula
VI:
##STR00093##
wherein:
[0515] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0516] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0517] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0518] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.nNH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0519] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0520] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.nNH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
or a pharmaceutically acceptable salt thereof.
[0521] In some embodiments, R.sup.2 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.2 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2
is H.
[0522] In any of the above embodiments, R.sup.4 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.4 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4
is H.
[0523] In any of the above embodiments, R.sup.5 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.5 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5
is H.
[0524] In any of the above embodiments, R.sup.6 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.6 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.6
is H.
[0525] In any of the above embodiments, R.sup.1 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.1 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.1 is
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4.
[0526] In any of the above embodiments, R.sup.3 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.3 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.3 is
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4.
[0527] In some embodiments:
[0528] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0529] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.n)NC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0530] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0531] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0532] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0533] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4.
[0534] In some embodiments:
[0535] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0536] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0537] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0538] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0539] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0540] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0541] In some embodiments:
[0542] R.sup.2 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0543] R.sup.4 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0544] R.sup.5 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0545] R.sup.6 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0546] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; and
[0547] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0548] In some embodiments:
[0549] R.sup.2 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0550] R.sup.4 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0551] R.sup.5 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0552] R.sup.6 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0553] R.sup.1 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; and
[0554] R.sup.3 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4.
[0555] In some embodiments:
[0556] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are H;
[0557] R.sup.1 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4; and
[0558] R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4.
[0559] In some embodiments, the compound is
##STR00094##
[0560] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0561] The present disclosure also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0562] The present disclosure also provides methods of preventing
or treating candidiasis (oral, and/or disseminated) or an
aspergillus infection in a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
VI:
##STR00095##
wherein:
[0563] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0564] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0565] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,--C.ident.C--CH.sub.2NC(.dbd.N)NH.s-
ub.2, or --C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n
is 2, 3, or 4;
[0566] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0567] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0568] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
or a pharmaceutically acceptable salt thereof.
[0569] In some embodiments, R.sup.2 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.2 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2
is H.
[0570] In any of the above embodiments, R.sup.4 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.4 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4
is H.
[0571] In any of the above embodiments, R.sup.5 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.5 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5
is H.
[0572] In any of the above embodiments, R.sup.6 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.6 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.6
is H.
[0573] In any of the above embodiments, R.sup.1 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.1 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.1 is
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4.
[0574] In any of the above embodiments, R.sup.3 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.3 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.3 is
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4.
[0575] In some embodiments:
[0576] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0577] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0578] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0579] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0580] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0581] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4.
[0582] In some embodiments:
[0583] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0584] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0585] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0586] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0587] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0588] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0589] In some embodiments:
[0590] R.sup.2 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0591] R.sup.4 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0592] R.sup.5 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0593] R.sup.6 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0594] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; and
[0595] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0596] In some embodiments:
[0597] R.sup.2 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0598] R.sup.4 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0599] R.sup.5 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0600] R.sup.6 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0601] R.sup.1 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; and
[0602] R.sup.3 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4.
[0603] In some embodiments:
[0604] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 is H;
[0605] R.sup.1 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4; and
[0606] R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4.
[0607] In some embodiments, the compound is
##STR00096##
[0608] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula VI:
##STR00097##
wherein:
[0609] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0610] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0611] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0612] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0613] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0614] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
or a pharmaceutically acceptable salt thereof.
[0615] In some embodiments, R.sup.2 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.2 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.2
is H.
[0616] In any of the above embodiments, R.sup.4 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.4 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.4
is H.
[0617] In any of the above embodiments, R.sup.5 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.5 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5 is
H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.5
is H.
[0618] In any of the above embodiments, R.sup.6 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.6 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.6 is
H or--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.6
is H.
[0619] In any of the above embodiments, R.sup.1 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.1 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.1 is
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4.
[0620] In any of the above embodiments, R.sup.3 is H,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4; or
R.sup.3 is --NH(CH.sub.2).sub.nNH2, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; or R.sup.3 is
--(CH.sub.2).sub.nNH.sub.2 or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; or R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0621] In some embodiments:
[0622] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0623] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0624] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0625] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0626] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0627] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4.
[0628] In some embodiments:
[0629] R.sup.2 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0630] R.sup.4 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0631] R.sup.5 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0632] R.sup.6 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0633] R.sup.1 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
and
[0634] R.sup.3 is H, --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2, or
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, where n is 2, 3, or 4;
[0635] In some embodiments:
[0636] R.sup.2 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0637] R.sup.4 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0638] R.sup.5 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0639] R.sup.6 is H, --(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4;
[0640] R.sup.1 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4; and
[0641] R.sup.3 is --NH(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNH.sub.2, or --O--(CH.sub.2).sub.nNH.sub.2, where
n is 2, 3, or 4.
[0642] In some embodiments:
[0643] R.sup.2 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0644] R.sup.4 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0645] R.sup.5 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0646] R.sup.6 is H or --(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4;
[0647] R.sup.1 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4; and
[0648] R.sup.3 is --(CH.sub.2).sub.nNH.sub.2 or
--O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3, or 4.
[0649] In some embodiments:
[0650] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 is H;
[0651] R.sup.1 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4; and
[0652] R.sup.3 is --O--(CH.sub.2).sub.nNH.sub.2, where n is 2, 3,
or 4.
[0653] In some embodiments, the compound is
##STR00098##
[0654] The present disclosure also provides compounds of Formula
VII:
##STR00099##
wherein:
[0655] each R.sup.1 is, independently, H, --C.sub.1-C.sub.8alkyl,
--C.sub.1-C.sub.8alkoxy, halo, --OH, --CF.sub.3, or --CN;
[0656] each R.sup.2 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0657] In some embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.8alkyl, halo, --OH, --CF.sub.3, or --CN. In some
embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.3alkyl, halo, --CF.sub.3, or --CN. In some
embodiments, each R.sup.1 is methyl or halo. In some embodiments,
each R.sup.1 is Br, F, or Cl.
[0658] In any of the above embodiments, each R.sup.2 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is, independently, 1 to 4. In some embodiments, each R.sup.2
is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4. In some embodiments, each R.sup.2 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or
2.
[0659] In some embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.8alkyl, halo, --OH, --CF.sub.3, or --CN; and each
R.sup.2 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0660] In some embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.3alkyl, halo, --CF.sub.3, or --CN; and each R.sup.2
is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4.
[0661] In some embodiments, each R.sup.1 is methyl or halo; and
each R.sup.2 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is 1 or 2.
[0662] In some embodiments, the compound is:
##STR00100##
or a pharmaceutically acceptable salt thereof.
[0663] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0664] The present disclosure also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0665] The present disclosure also provides methods of preventing
or treating candidiasis (oral and/or disseminated) or an
aspergillus infection. In a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
VII:
##STR00101##
wherein:
[0666] each R.sup.1 is, independently, H, --C.sub.1-C.sub.8alkyl,
--C.sub.1-C.sub.8alkoxy, halo, --OH, --CF.sub.3, or --CN;
[0667] each R.sup.2 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0668] In some embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.8alkyl, halo, --OH, --CF.sub.3, or --CN. In some
embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.3alkyl, halo, --CF.sub.3, or --CN. In some
embodiments, each R.sup.1 is methyl or halo. In some embodiments,
each R.sup.1 is Br, F, or Cl.
[0669] In any of the above embodiments, each R.sup.2 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is, independently, 1 to 4. In some embodiments, each R.sup.2
is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4. In some embodiments, each R.sup.2 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or
2.
[0670] In some embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.8alkyl, halo, --OH, --CF.sub.3, or --CN; and each
R.sup.2 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0671] In some embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.3alkyl, halo, --CF.sub.3, or --CN; and each R.sup.2
is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4.
[0672] In some embodiments, each R.sup.1 is methyl or halo; and
each R.sup.2 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is 1 or 2.
[0673] In some embodiments, the compound is:
##STR00102##
or a pharmaceutically acceptable salt thereof.
[0674] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula VII:
##STR00103##
wherein:
[0675] each R.sup.1 is, independently, H, --C.sub.1-C.sub.8alkyl,
--C.sub.1-C.sub.8alkoxy, halo, --OH, --CF.sub.3, or --CN;
[0676] each R.sup.2 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0677] In some embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.8alkyl, halo, --OH, --CF.sub.3, or --CN. In some
embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.3alkyl, halo, --CF.sub.3, or --CN. In some
embodiments, each R.sup.1 is methyl or halo. In some embodiments,
each R.sup.1 is Br, F, or Cl.
[0678] In any of the above embodiments, each R.sup.2 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is, independently, 1 to 4. In some embodiments, each R.sup.2
is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4. In some embodiments, each R.sup.2 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or
2.
[0679] In some embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.8alkyl, halo, --OH, --CF.sub.3, or --CN; and each
R.sup.2 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0680] In some embodiments, each R.sup.1 is, independently,
--C.sub.1-C.sub.3alkyl, halo, --CF.sub.3, or --CN; and each R.sup.2
is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4.
[0681] In some embodiments, each R.sup.1 is methyl or halo; and
each R.sup.2 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is 1 or 2.
[0682] In some embodiments, the compound is:
##STR00104##
or a pharmaceutically acceptable salt thereof.
[0683] The present disclosure also provides compounds of Formula
VIII:
##STR00105##
wherein:
[0684] R.sup.1 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0685] R.sup.2 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0686] R.sup.3 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0687] R.sup.4 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0688] R.sup.5 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0689] R.sup.6 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0690] R.sup.7 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0691] R.sup.8 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0692] R.sup.9 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; or a pharmaceutically acceptable salt thereof.
[0693] In some embodiments, R.sup.1 is halo, --CF.sub.3,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.1 is halo, --CF.sub.3, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.3NH.sub.2, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2.
[0694] In any of the above embodiments, R.sup.2 is halo,
--CF.sub.3, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.2 is halo, --CF.sub.3, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.3NH.sub.2, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2.
[0695] In any of the above embodiments, R.sup.3 is H, --CF.sub.3,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.3 is H, --CF.sub.3, --O--(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2.
[0696] In any of the above embodiments, R.sup.4 is H, halo,
--O--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.nNH.sub.2, or
--C.ident.C--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some
embodiments, R.sup.4 is H, halo, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2.
[0697] In any of the above embodiments, R.sup.5 is H, halo,
--O--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.nNH.sub.2, or
--C.ident.C--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some
embodiments, R.sup.5 is H, halo, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2.
[0698] In any of the above embodiments, R.sup.6 is H,
--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.6 is H, --(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2.
[0699] In any of the above embodiments, R.sup.7 is H,
--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.7 is H, --(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2.
[0700] In any of the above embodiments, R.sup.8 is H or halo.
[0701] In any of the above embodiments, R.sup.9 is H or halo.
[0702] In some embodiments, R.sup.1 is halo, --CF.sub.3,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.3NH.sub.2,
--O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2; R.sup.2 is halo,
--CF.sub.3, --(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.3NH.sub.2,
--O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2; R.sup.3 is H, --CF.sub.3,
--O--(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2; R.sup.4 is H, halo,
--O--(CH.sub.2).sub.3NH.sub.2, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2; R.sup.5 is H,
halo, --O--(CH.sub.2).sub.3NH.sub.2, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2; R.sup.6 is H,
--(CH.sub.2).sub.3NH.sub.2 or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2; R.sup.7 is H,
--(CH.sub.2).sub.3NH.sub.2 or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2; R.sup.8 is H or halo; and
R.sup.9 is H or halo.
[0703] In some embodiments, the compound is chosen from
##STR00106## ##STR00107## ##STR00108## ##STR00109##
or a pharmaceutically acceptable salt thereof.
[0704] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0705] The present disclosure also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0706] The present disclosure also provides methods of preventing
or treating candidiasis (oral and/or disseminated) or an
aspergillus infection in a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
VIII:
##STR00110##
wherein:
[0707] R.sup.1 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0708] R.sup.2 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0709] R.sup.3 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0710] R.sup.4 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0711] R.sup.5 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0712] R.sup.6 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0713] R.sup.7 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0714] R.sup.8 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0715] R.sup.9 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; or a pharmaceutically acceptable salt thereof.
[0716] In some embodiments, R.sup.1 is halo, --CF.sub.3,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.1 is halo, --CF.sub.3, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.3NH.sub.2, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2.
[0717] In any of the above embodiments, R.sup.2 is halo,
--CF.sub.3, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.2 is halo, --CF.sub.3, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.3NH.sub.2, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2.
[0718] In any of the above embodiments, R.sup.3 is H, --CF.sub.3,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.3 is H, --CF.sub.3, --O--(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2.
[0719] In any of the above embodiments, R.sup.4 is H, halo,
--O--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.nNH.sub.2, or
--C.ident.C--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some
embodiments, R.sup.4 is H, halo, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2.
[0720] In any of the above embodiments, R.sup.5 is H, halo,
--O--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.nNH.sub.2, or
--C.ident.C--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some
embodiments, R.sup.5 is H, halo, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2.
[0721] In any of the above embodiments, R.sup.6 is H,
--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.6 is H, --(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2.
[0722] In any of the above embodiments, R.sup.7 is H,
--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.7 is H, --(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2.
[0723] In any of the above embodiments, R.sup.8 is H or halo.
[0724] In any of the above embodiments, R.sup.9 is H or halo.
[0725] In some embodiments, R.sup.1 is halo, --CF.sub.3,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.3NH.sub.2,
--O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2; R.sup.2 is halo,
--CF.sub.3, --(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.3NH.sub.2,
--O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2; R.sup.3 is H, --CF.sub.3,
--O--(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2; R.sup.4 is H, halo,
--O--(CH.sub.2).sub.3NH.sub.2, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2; R.sup.5 is H,
halo, --O--(CH.sub.2).sub.3NH.sub.2, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2; R.sup.6 is H,
--(CH.sub.2).sub.3NH.sub.2 or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2; R.sup.7 is H,
--(CH.sub.2).sub.3NH.sub.2 or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2; R.sup.8 is H or halo; and
R.sup.9 is H or halo.
[0726] In some embodiments, the compound is chosen from
##STR00111## ##STR00112## ##STR00113## ##STR00114##
or a pharmaceutically acceptable salt thereof.
[0727] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula VIII:
##STR00115##
wherein:
[0728] R.sup.1 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0729] R.sup.2 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0730] R.sup.3 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0731] R.sup.4 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0732] R.sup.5 is H, halo, haloalkyl, 13 NH.sub.2,
--C.sub.1-3alkyl, --NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0733] R.sup.6 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0734] R.sup.7 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4;
[0735] R.sup.8 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; and
[0736] R.sup.9 is H, halo, haloalkyl, --NH.sub.2, --C.sub.1-3alkyl,
--NH(CH.sub.2).sub.nNH.sub.2,
--NH(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--CH.dbd.CH--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2--NC(.dbd.N)NH.sub.2, where n is 2, 3,
or 4; or a pharmaceutically acceptable salt thereof.
[0737] In some embodiments, R.sup.1 is halo, --CF.sub.3,
--(CH.sub.2).sub.nNH.sub.2, --O--(CH.sub.2).sub.nNH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.1 is halo, --CF.sub.3, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.3NH.sub.2, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2.
[0738] In any of the above embodiments, R.sup.2 is halo,
--CF.sub.3, --(CH.sub.2).sub.nNH.sub.2,
--O--(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.2 is halo, --CF.sub.3, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.3NH.sub.2, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2.
[0739] In any of the above embodiments, R.sup.3 is H, --CF.sub.3,
--O--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.3 is H, --CF.sub.3, --O--(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2.
[0740] In any of the above embodiments, R.sup.4 is H, halo,
--O--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.nNH.sub.2, or
--C.ident.C--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some
embodiments, R.sup.4 is H, halo, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2.
[0741] In any of the above embodiments, R.sup.5 is H, halo,
--O--(CH.sub.2).sub.nNH.sub.2, --(CH.sub.2).sub.nNH.sub.2,
--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.nNH.sub.2, or
--C.ident.C--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some
embodiments, R.sup.5 is H, halo, --O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2.
[0742] In any of the above embodiments, R.sup.6 is H,
--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.6 is H, --(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2.
[0743] In any of the above embodiments, R.sup.7 is H,
--(CH.sub.2).sub.nNH.sub.2, or
--O--(CH.sub.2).sub.nNC(.dbd.N)NH.sub.2. In some embodiments,
R.sup.7 is H, --(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2.
[0744] In any of the above embodiments, R.sup.8 is H or halo.
[0745] In any of the above embodiments, R.sup.9 is H or halo.
[0746] In some embodiments, R.sup.1 is halo, --CF.sub.3,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.3NH.sub.2,
--O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2; R.sup.2 is halo,
--CF.sub.3, --(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.3NH.sub.2,
--O--(CH.sub.2).sub.3NH.sub.2,
--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2, --C.ident.C--CH.sub.2NH.sub.2, or
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2; R.sup.3 is H, --CF.sub.3,
--O--(CH.sub.2).sub.3NH.sub.2, or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2; R.sup.4 is H, halo,
--O--(CH.sub.2).sub.3NH.sub.2, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--CH.dbd.CH--CH.sub.2NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2; R.sup.5 is H,
halo, --O--(CH.sub.2).sub.3NH.sub.2, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--CH.sub.2NH.sub.2, --CH.dbd.CH--CH.sub.2NH.sub.2,
--CH.dbd.CH--CH.sub.2NC(.dbd.N)NH.sub.2,
--C.ident.C--(CH.sub.2).sub.2NH.sub.2,
--C.ident.C--CH.sub.2NC(.dbd.N)NH.sub.2, or
--C.ident.C--(CH.sub.2).sub.2NC(.dbd.N)NH.sub.2; R.sup.6 is H,
--(CH.sub.2).sub.3NH.sub.2 or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2; R.sup.7 is H,
--CH.sub.2).sub.3NH.sub.2 or
--O--(CH.sub.2).sub.3NC(.dbd.N)NH.sub.2; R.sup.8 is H or halo; and
R.sup.9 is H or halo.
[0747] In some embodiments, the compound is chosen from
##STR00116## ##STR00117## ##STR00118## ##STR00119##
or a pharmaceutically acceptable salt thereof.
[0748] The present disclosure also provides compounds of Formula
IX:
##STR00120##
wherein:
[0749] each X is, independently, O or S;
[0750] each Y is, independently, O or S;
[0751] each R.sub.2 is, independently, --C.sub.1-C.sub.9 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
[0752] each R.sub.3 is, independently, --C.sub.1-C.sub.9 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
and
[0753] each R.sub.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0754] In some embodiments, each X is O.
[0755] In any of the above embodiments, each Y is O.
[0756] In any of the above embodiments, each R.sub.2 is,
independently, --C.sub.1-C.sub.6 straight or branched alkyl
optionally substituted with one or more --NH.sub.2,
--N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2; or each R.sub.2
is, independently, --C.sub.1-C.sub.6 straight or branched alkyl; or
each R.sub.2 is, independently, --C.sub.1-C.sub.4 straight alkyl;
or each R.sub.2 is methyl.
[0757] In any of the above embodiments, each R.sub.3 is,
independently, --C.sub.1-C.sub.6 straight or branched alkyl
optionally substituted with one or more --NH.sub.2,
--N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2; or each R.sub.3
is, independently, --C.sub.1-C.sub.6 straight or branched alkyl; or
each R.sub.3 is, independently, --C.sub.3-C.sub.5 straight or
branched alkyl; or each R.sub.3 is
--(CH.sub.2).sub.2--CH(CH.sub.3).sub.2.
[0758] In any of the above embodiments, each R.sub.4 is
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an integer
from 1 or 2; or each R.sub.4 is, independently
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an integer
from 1 or 2; or each R.sub.4 is
--(CH.sub.2)--NH--C(.dbd.NH)NH.sub.2.
[0759] In some embodiments,
[0760] each X and Y are O;
[0761] each R.sub.2 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
[0762] each R.sub.3 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
and
[0763] each R.sub.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 or 2.
[0764] In some embodiments,
[0765] each X and Y are O;
[0766] each R.sub.2 is, independently, --C.sub.1-C.sub.6straight or
branched alkyl;
[0767] each R.sub.3 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl; and
[0768] each R.sub.4 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an integer
from 1 or 2.
[0769] In some embodiments,
[0770] each R.sub.2 is, independently, --C.sub.1-C.sub.4 straight
alkyl;
[0771] each R.sub.3 is, independently, --C.sub.3-C.sub.5 straight
or branched alkyl; and
[0772] each R.sub.4 is --(CH.sub.2)--NH--C(.dbd.NH)NH.sub.2.
[0773] In some embodiments,
[0774] each X and Y are O;
[0775] each R.sub.2 is methyl;
[0776] each R.sub.3 is --(CH.sub.2).sub.2--CH(CH.sub.3).sub.2;
and
[0777] each R.sub.4 is --(CH.sub.2)--NH--C(.dbd.NH)NH.sub.2.
[0778] In some embodiments, the compound is
##STR00121##
or a pharmaceutically acceptable salt thereof.
[0779] The present disclosure also provides methods of preventing
or treating candidiasis (oral and/or disseminated) or an
aspergillus infection in a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
IX:
##STR00122##
wherein:
[0780] each X is, independently, O or S;
[0781] each Y is, independently, O or S;
[0782] each R.sub.2 is, independently, --C.sub.1-C.sub.9 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
[0783] each R.sub.3 is, independently, --C.sub.1-C.sub.9 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
and
[0784] each R.sub.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0785] In some embodiments, each X is O.
[0786] In any of the above embodiments, each Y is O.
[0787] In any of the above embodiments, each R.sub.2 is,
independently, --C.sub.1-C.sub.6 straight or branched alkyl
optionally substituted with one or more --NH.sub.2,
--N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2; or each R.sub.2
is, independently, --C.sub.1-C.sub.6 straight or branched alkyl; or
each R.sub.2 is, independently, --C.sub.1-C.sub.4 straight alkyl;
or each R.sub.2 is methyl.
[0788] In any of the above embodiments, each R.sub.3 is,
independently, --C.sub.1-C.sub.6 straight or branched alkyl
optionally substituted with one or more --NH.sub.2,
--N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2; or each R.sub.3
is, independently, --C.sub.1-C.sub.6 straight or branched alkyl; or
each R.sub.3 is, independently, --C.sub.3-C.sub.5 straight or
branched alkyl; or each R.sub.3 is
--(CH.sub.2).sub.2--CH(CH.sub.3).sub.2.
[0789] In any of the above embodiments, each R.sub.4 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an integer
from 1 or 2; or each R.sub.4 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an integer
from 1 or 2; or each R.sub.4 is
--(CH.sub.2)--NH--C(.dbd.NH)NH.sub.2.
[0790] In some embodiments,
[0791] each X and Y are O;
[0792] each R.sub.2 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
[0793] each R.sub.3 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
and
[0794] each R.sub.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 or 2.
[0795] In some embodiments,
[0796] each X and Y are O;
[0797] each R.sub.2 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl;
[0798] each R.sub.3 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl; and
[0799] each R.sub.4 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an integer
from 1 or 2.
[0800] In some embodiments,
[0801] each R.sub.2 is, independently, --C.sub.1-C.sub.4 straight
alkyl;
[0802] each R.sub.3 is, independently, --C.sub.3-C.sub.5 straight
or branched alkyl; and
[0803] each R.sub.4 is --(CH.sub.2)--NH--C(.dbd.NH)NH.sub.2.
[0804] In some embodiments,
[0805] each X and Y are O;
[0806] each R.sub.2 is methyl;
[0807] each R.sub.3 is --(CH.sub.2).sub.2--CH(CH.sub.3).sub.2;
and
[0808] each R.sub.4 is --(CH.sub.2)--NH--C(.dbd.NH)NH.sub.2.
[0809] In some embodiments, the compound is
##STR00123##
or a pharmaceutically acceptable salt thereof.
[0810] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula IX:
##STR00124##
wherein:
[0811] each X is, Independently, O or S;
[0812] each Y is, independently, O or S;
[0813] each R.sub.2 is, independently, --C.sub.1-C.sub.9 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
[0814] each R.sub.3 is, independently, --C.sub.1-C.sub.9 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
and
[0815] each R.sub.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0816] In some embodiments, each X is O.
[0817] In any of the above embodiments, each Y is O.
[0818] In any of the above embodiments, each R.sub.2 is,
independently, --C.sub.1-C.sub.6 straight or branched alkyl
optionally substituted with one or more --NH.sub.2,
--N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2; or each R.sub.2
is, independently, --C.sub.1-C.sub.6 straight or branched alkyl; or
each R.sub.2 is, independently, --C.sub.1-C.sub.4 straight alkyl;
or each R.sub.2 is methyl.
[0819] In any of the above embodiments, each R.sub.3 is,
independently, --C.sub.1-C.sub.6 straight or branched alkyl
optionally substituted with one or more --NH.sub.2,
--N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2; or each R.sub.3
is, independently, --C.sub.1-C.sub.6 straight or branched alkyl; or
each R.sub.3 is, independently, --C.sub.3-C.sub.5 straight or
branched alkyl; or each R.sub.3 is
--(CH.sub.2).sub.2--CH(CH.sub.3).sub.2.
[0820] In any of the above embodiments, each R.sub.4 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an integer
from 1 or 2; or each R.sub.4 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an integer
from 1 or 2; or each R.sub.4 is
--(CH.sub.2)--NH--C(.dbd.NH)NH.sub.2.
[0821] In some embodiments,
[0822] each X and Y are O;
[0823] each R.sub.2 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
[0824] each R.sub.3 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl optionally substituted with one or more
--NH.sub.2, --N(CH.sub.3).sub.2 or --NH--C(.dbd.NH)NH.sub.2;
and
[0825] each R.sub.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 or 2.
[0826] In some embodiments,
[0827] each X and Y are O;
[0828] each R.sub.2 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl;
[0829] each R.sub.3 is, independently, --C.sub.1-C.sub.6 straight
or branched alkyl; and
[0830] each R.sub.4 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an integer
from 1 or 2.
[0831] In some embodiments,
[0832] each R.sub.2 is, independently, --C.sub.1-C.sub.4 straight
alkyl;
[0833] each R.sub.3 is, independently, --C.sub.3-C.sub.5 straight
or branched alkyl; and
[0834] each R.sub.4 is --(CH.sub.2)--NH--C(.dbd.NH)NH.sub.2.
[0835] In some embodiments,
[0836] each X and Y are O,
[0837] each R.sub.2 is methyl;
[0838] each R.sub.3 is --(CH.sub.2).sub.2--CH(CH.sub.3).sub.2;
and
[0839] each R.sub.4 is --(CH.sub.2)--NH--C(.dbd.NH)NH.sub.2.
[0840] In some embodiments, the compound is
##STR00125##
or a pharmaceutically acceptable salt thereof.
[0841] The present disclosure also provides compounds of Formula
X:
##STR00126##
wherein:
[0842] X is
##STR00127##
and
[0843] each R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0844] In some embodiments, each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 1 or 2; or
each R.sup.1 is, independently --(CH.sub.2).sub.n--NH--C((50
NH)NH.sub.2, where n is 1 or 2; or each R.sup.1 is
--(CH.sub.2).sub.2--NHC(.dbd.NH)NH.sub.2.
[0845] In some embodiments, the compound is
##STR00128##
or a pharmaceutically acceptable salt thereof.
[0846] The present disclosure also provides methods of preventing
or treating candidiasis (oral and/or disseminated) or an
aspergillus infection in a mammal comprising administering to the
mammal in need thereof an effective amount of a compound of Formula
X:
##STR00129##
wherein:
[0847] X is
##STR00130##
and
[0848] each R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0849] In some embodiments, each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 1 or 2; or
each R.sup.1 is, independently
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 1 or 2; or
each R.sup.1 is --(CH.sub.2).sub.2--NHC(.dbd.NH)NH.sub.2.
[0850] In some embodiments, the compound is
##STR00131##
or a pharmaceutically acceptable salt thereof.
[0851] The present disclosure also provides methods of killing or
inhibiting the growth of a Candida or Aspergillus species
comprising contacting the Candida or Aspergillus species with an
effective amount of a compound of Formula X:
##STR00132##
wherein:
[0852] X is
##STR00133##
and
[0853] each R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is an
integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0854] In some embodiments, each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 1 or 2; or
each R.sup.1 is, independently
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 1 or 2; or
each R.sup.1 is --(CH.sub.2).sub.2--NHC(.dbd.NH)NH.sub.2.
[0855] In some embodiments, the compound is
##STR00134##
or a pharmaceutically acceptable salt thereof.
[0856] In any of the above embodiments, one or more of the
compounds recited herein may be more effective (better IC.sub.50 or
EC.sub.50 value) against a Candida species (such a C. albicans)
than any one or more of E. coli 25922, S. aureus 27660, E. faecalis
29212, P. aeruginosa 10145, and K. pneumoniae 13883. Thus, one or
more of the compounds recited herein may be more selective for a
Candida species (such a C. albicans) than any one or more of E.
coli 25922, S. aureus 27660, E. faecalis 29212, P. aeruginosa
10145, and K. pneumoniae 13883. Some of the active compounds
described herein are, thus, highly selective for C. albicans over
Gram-positive and Gram-negative bacteria. This may be advantageous
in situations where one skilled in the art does not desire to
disrupt normal flora within an individual. Thus, when administered
to a mammal, any one ore more of the compounds recited herein may
kill or inhibit the growth of Candida (such a C. albicans) or
Aspergillus species without significantly disturbing the normal
flora of the individual.
[0857] Polyamides and polyesters that are useful in the present
disclosure can be prepared by typical condensation polymerization
and addition polymerization processes (see, for example, G. Odian,
Principles of Polymerization, John Wiley & Sons, Third Edition
(1991), and M. Steven, Polymer Chemistry, Oxford University Press
(1999)). Most commonly, the polyamides are prepared by a) thermal
dehydration of amine salts of carboxylic acids, b) reaction of acid
chlorides with amines, and c) aminolysis of esters. Methods a) and
c) are of limited use in polymerizations of aniline derivatives
which are generally prepared utilizing acid chlorides. The skilled
chemist, however, will recognize that there are many alternative
active acylating agents, for example, phosphoryl anhydrides, active
esters or azides, which may replace an acid chloride and which,
depending of the particular polymer being prepared, may be superior
to an acid chloride. The acid chloride route is probably the most
versatile and has been used extensively for the synthesis of
aromatic polyamides.
[0858] Homopolymers derived from substituted aminobenzoic acid
derivatives can also prepared in a stepwise fashion. A stepwise
process comprises coupling an N-protected amino acid to an amine
(or hydroxy group) and subsequently removing the amine-protecting
group and repeating the process. These techniques have been highly
refined for synthesis of specific peptides, allow for the synthesis
of specific sequences, and both solid-phase and solution techniques
for peptide synthesis are directly applicable to the present
disclosure. An alternative embodiment is the corresponding
polysulfonamides that can be prepared in analogous fashion by
substituting sulfonyl chlorides for carboxylic acid chlorides.
[0859] The most common method for the preparation of polyureas is
the reaction of diamines with diisocyanates (see, Yamaguchi et al.,
Polym. Bull., 2000, 44, 247). This exothermic reaction can be
carried out by solution techniques or by interfacial techniques.
One skilled in organic and polymer chemistry will appreciate that
the diisocyanate can be replaced with a variety of other
bis-acylating agents, such as phosgene or
N,N'-(diimidazolyl)carbonyl, with similar results. Polyurethanes
are prepared by comparable techniques using a diisocyanate and a
dialcohol or by reaction of a diamine with a bis-chloroformate.
[0860] The syntheses of compounds described herein can be carried
out by routine and/or known methods such as those disclosed in, for
example, U.S. Patent Application Publication Nos. 2005-0287108,
2006-0041023, U.S. Pat. No. 7,173,102, International Publication
Nos. WO 2005/123660, WO 2004/082643, and WO 2006/093813, and U.S.
Application Publication No. 2010-0081665, each of which is
incorporated herein by reference in its entirety. Numerous pathways
are available to incorporate polar and nonpolar side chains.
Phenolic groups on the monomer can be alkylated. Alkylation of the
commercially available phenol will be accomplished with standard
Williamson ether synthesis for the non-polar side chain with ethyl
bromide as the alkylating agent. Polar sidechains can be introduced
with bifunctional alkylating agents such as
BOC-NH(CH.sub.2).sub.2Br. Alternately, the phenol group can be
alkylated to install the desired polar side chain function by
employing the Mitsonobu reaction with BOC-NH(CH.sub.2).sub.2-OH,
triphenyl phosphine, and diethyl acetylenedicarboxylate. Standard
conditions for reduction of the nitro groups and hydrolysis of the
ester afford the amino acid. With the aniline and benzoic acid in
hand, coupling can be effected under a variety of conditions.
Alternatively, the hydroxy group of the (di)nitrophenol can be
converted to a leaving group and a functionality introduced under
nucleophilic aromatic substitution conditions. Other potential
scaffolds that can be prepared with similar sequences are methyl
2-nitro-4-hydroxybenzoate and methyl 2-hydroxy-4-nitrobenzoate.
[0861] Compounds described herein can also be synthesized by
solid-phase synthetic procedures well know to those of skill in the
art (see, Tew et al., Proc. Natl. Acad. Sci. USA, 2002, 99,
5110-5114; Barany et al., Int. J. Pept. Prot. Res., 1987, 30,
705-739, Solid-phase Synthesis: A Practical Guide, Kates, S. A.,
and Albericio, F., eds., Marcel Dekker, New York (2000); and
Dorwald, F. Z., Organic Synthesis on Solid Phase: Supports,
Linkers, Reactions, 2nd Ed., Wiley-VCH, Weinheim (2002)).
[0862] The compounds described herein can also be designed using
computer-aided computational techniques, such as de novo design
techniques, to embody the amphiphilic properties. In general, de
novo design of compounds is performed by defining a
three-dimensional framework of the backbone assembled from a
repeating sequence of monomers using molecular dynamics and quantum
force field calculations. Next, side groups are computationally
grafted onto the backbone to maximize diversity and maintain
drug-like properties. The best combinations of functional groups
are then computationally selected to produce a cationic,
amphiphilic structures. Representative compounds can be synthesized
from this selected library to verify structures and test their
biological activity. Novel molecular dynamic and coarse grain
modeling programs have also been developed for this approach
because existing force fields developed for biological molecules,
such as peptides, were unreliable in these oligomer applications
(see, Car et al., Phys. Rev. Lett., 1985, 55, 2471-2474; Siepmann
et al., Mol. Phys., 1992, 75, 59-70; Martin et al., J. Phys. Chem.,
1999, 103, 4508-4517; and Brooks et al., J. Comp. Chem., 1983, 4,
187-217). Several chemical structural series of compounds have been
prepared. See, for example, International Publication No. WO
2002/100295, which is incorporated herein by reference in its
entirety. The compounds described herein can be prepared in a
similar manner. Molecular dynamic and coarse grain modeling
programs can be used for a design approach. See, for example, U.S.
Application Publication No. 2004-0107056, and U.S. Application
Publication No. 2004-0102941, each of which is incorporated herein
by reference in its entirety.
[0863] After verifying the suitability of the force field by
comparing computed predictions of the structure and thermodynamic
properties to molecules that have similar torsional patterns and
for which experimental data are available, the fitted torsions can
then be combined with bond stretching, bending, one-four, van der
Waals, and electrostatic potentials borrowed from the CHARMM (see,
Brooks et al., J. Comp. Chem., 1983, 4, 187-217) and TraPPE (Martin
et al., J. Phys. Chem., 1999, 103, 4508-4517; and Wick et al., J.
Phys. Chem., 2000, 104, 3093-3104) molecular dynamics force fields.
To identify conformations that can adopt periodic folding patterns
with polar groups and apolar groups lined up on the opposite sides,
initial structures can be obtained with the Gaussian package (see,
Frisch et al., Gaussian 98 (revision A.7) Gaussian Inc.,
Pittsburgh, Pa. 1998). Then, the parallelized plane-wave
Car-Parrinello CP-MD (see, Car et al., Phys. Rev. Lett., 1985, 55,
2471-2474) program, (see Rothlisberger et al., J. Chem. Phys.,
1996, 3692-3700) can be used to obtain energies at the minimum and
constrained geometries. The conformations of the compounds without
side-chains can be investigated in the gas phase. Both MD and MC
methods can be used to sample the conformations. The former is
useful for global motions of the compound. With biasing techniques
(see, Siepmann et al., Mol. Phys., 1992, 75, 59-70; Martin et al.,
J. Phys. Chem., 1999, 103, 4508-4517; and Vlugt et al., Mol. Phys.,
1998, 94, 727-733), the latter allows efficient sampling for
compounds with multiple local minimum configurations that are
separated by relatively large barriers.
[0864] The potential conformations are examined for positions to
attach pendant groups that will impart amphiphilic character to the
secondary structure. Compounds selected from the gas phase studies
with suitable backbone conformations and with side-chains at the
optimal positions to introduce amphiphilicity can be further
evaluated in a model interfacial system. n-hexane/water can be
chosen because it is simple and cheap for calculations while it
mimics well the lipid/water bilayer environment. Compound secondary
structures that require intercompound interactions can be
identified by repeating the above-mentioned calculations using a
periodically repeated series of unit cells of various symmetries
(so called variable cell molecular dynamics or Monte Carlo
technique) with or without solvent. The results of these
calculations can guide the selection of candidates for
synthesis.
[0865] The compounds described herein can be administered in any
conventional manner by any route where they are active.
Administration can be systemic, topical, or oral. For example,
administration can be, but is not limited to, parenteral,
subcutaneous, intravenous, intramuscular, intraperitoneal,
transdermal, oral, buccal, sublingual, or ocular routes, or
intravaginally, by inhalation, by depot injections, or by implants.
The mode of administration can depend on the pathogen or microbe to
be targeted. The selection of the specific route of administration
can be selected or adjusted by the clinician according to methods
known to the clinician to obtain the desired clinical response.
[0866] In some embodiments, it may be desirable to administer one
or more compounds, or a pharmaceutically acceptable salt thereof,
locally to an area in need of treatment. This may be achieved, for
example, and not by way of limitation, by local infusion during
surgery, topical application, e.g., in conjunction with a wound
dressing after surgery, by injection, by means of a catheter, by
means of a suppository, or by means of an implant, wherein the
implant is of a porous, non-porous, or gelatinous material,
including membranes, such as sialastic membranes, or fibers.
[0867] The compounds described herein can be administered either
alone or in combination (concurrently or serially) with other
pharmaceuticals. The compounds can be administered in combination
with anti-cancer or anti-neoplastic agents, or in combination with
other cancer therapies other than chemotherapy, such as, for
example, surgery or radiotherapy. In some embodiments, the
compounds described herein can also be administered in combination
with (i.e., as a combined formulation or as separate formulations)
with antibiotics (in particular, anti-yeast compounds), such as,
for example: 1) protein synthesis inhibitors including, but not
limited to, amikacin, anisomycin, apramycin, azithromycin,
blasticidine S, brefeldin A, butirosin, chloramphenicol,
chlortetracycline, clindamycin, clotrimazole, cycloheximide,
demeclocycline, dibekacin, dihydrostreptomycin, doxycycline,
duramycin, emetine, erythromycin, fusidic acid, G 418, gentamicin,
helvolic acid, hygromycin B, josamycin, kanamycin, kirromycin,
lincomycin, meclocycline, mepartricin, midecamycin, minocycline,
neomycin, netilmicin, nitrofurantoin, nourseothricin, oleandomycin,
oxytetracycline, paromomycin, puromycin, rapamycin, ribostamycin,
rifampicin, rifamycin, rosamicin, sisomicin, spectinomycin,
spiramycin, streptomycin, tetracycline, thiamphenicol,
thiostrepton, tobramycin, tunicamycin, tylosin, viomycin, and
virginiamycin; 2) DNA synthesis interfering agents including, but
not limited to, camptothecin, 10-deacetylbaccatin III, azacytidine,
7-aminoactinomycin D, 8-quinolinol, 9-dihydro-13-acetylbaccatin
III, aclarubicin, actinomycin D, actinomycin I, actinomycin V,
befilomycin A1, bleomycin, capreomycin, chromomycin, cinoxacin,
ciprofloxacin, cis-diammineplatinum(II) dichloride, coumermycin A1,
L(+)-lactic acid, cytochalasin B, cytochalasin D, dacarbazine,
daunorubicin, distamycin A, doxorubicin, echinomycin, enrofloxacin,
etoposide, flumequine, formycin, fumagillin, ganciclovir,
gliotoxin, lomefloxacin, metronidazole, mithramycin A, mitomycin C,
nalidixic acid, netropsin, nitrofurantoin, nogalamycin, nonactin,
novobiocin, ofloxacin, oxolinic acid, paclitaxel, phenazine,
phleomycin, pipemidic acid, rebeccamycin, sinefungin,
streptonigrin, streptozocin, succinylsulfathiazole, sulfadiazine,
sulfadimethoxine, sulfaguanidine purum, sulfamethazine,
sulfamonomethoxine, sulfanilamide, sulfaquinoxaline, sulfasalazine,
sulfathiazole, trimethoprim, tubercidin, 5-azacytidine, cordycepin,
and formycin A; 3) cell wall synthesis interfering agents
including, but not limited to, (+)-6-aminopenicillanic acid,
7-Aminodesacetoxycephalosporanic acid, amoxicillin, ampicillin,
azlocillin, bacitracin, carbenicillin, cefaclor, cefamandole,
cefazolin, cefmetazole, cefoperazone, cefotaxime, cefsulodin,
ceftriaxone, cephalexin, cephalosporin C, cephalothin, cephradine,
cloxacillin, D-cycloserine, dicloxacillin, D-penicillamine,
econazole, ethambutol, lysostaphin, moxalactam, nafcillin,
nikkomycin Z, nitrofurantoin, oxacillin, penicillic, penicillin G,
phenethicillin, phenoxymethylpenicillinic acid, phosphomycin,
pipemidic acid, piperacillin, ristomycin, and vancomycin; 4) cell
membrane permeability interfering agents (ionophores) including,
but not limited to, 2-mercaptopyridine, 4-bromocalcimycin A23187,
alamethicin, amphotericin B, calcimycin A23187, chlorhexidine,
clotrimazole, colistin, econazole, hydrocortisone, filipin,
gliotoxin, gramicidin A, gramicidin C, ionomycin, lasalocid A,
lonomycin A, monensin,
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, narasin,
nigericin, nisin, nonactin, nystatin, phenazine, pimaricin,
polymyxin B, DL-penicillamine, polymyxin B, praziquantel,
salinomycin, surfactin, and valinomycin; 5) enzyme inhibitors
including, but not limited to, (+)-usnic acid, (.+-.)-miconazole,
(S)-(+)-camptothecin, 1-deoxymannojirimycin,
2-heptyl-4-hydroxyquinoline N-oxide, cordycepin,
1,10-phenanthroline, 6-diazo-5-oxo-L-norleucine, 8-quinolinol,
antimycin, antipain, ascomycin, azaserine, bafilomycin, cerulenin,
chloroquine, cinoxacin, ciprofloxacin, mevastatin, concanamycin A,
concanamycin C, coumermycin A1, L(+)-lactic acid, cyclosporin A,
econazole, enrofloxacin, etoposide, flumequine, formycin A,
furazolidone, fusaric acid, geldanamycin, gliotoxin, gramicidin A,
gramicidin C, herbimycin A, iodomethacin, irgasan, lomefloxacin,
mycophenolic acid, myxothiazol,
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, nalidixic acid,
netropsin, niclosamide, nikkomycin, N-methyl-1-deoxynojirimycin,
nogalamycin, nonactin, novobiocin, ofloxacin, oleandomycin,
oligomycin, oxolinic acid, piericidin A, pipemidic acid, radicicol,
rapamycin, rebeccamycin, sinefungin, staurosporine, stigmatellin,
succinylsulfathiazole, succinylsulfathiazole, sulfadiazine,
sulfadimethoxine, sulfaguanidine, sulfamethazine,
sulfamonomethoxine, sulfanilamide, sulfaquinoxaline, sulfasalazine,
sulfathiazole, triacsin C, trimethoprim, and vineomycin A1; and 6)
membrane modifiers including, but not limited to, paracelsin. In
some embodiments, one or more compounds described herein can be
administered in combination with one or more anti-fungal drugs,
such as nystatin, miconazole, Gentian violet, or amphotericin
B.
[0868] The means and methods for administration are known in the
art and an artisan can refer to various pharmacologic references
for guidance (see, for example, Modern Pharmaceutics, Banker &
Rhodes, Marcel Dekker, Inc. (1979); and Goodman & Gilman's The
Pharmaceutical Basis of Therapeutics, 6th Edition, MacMillan
Publishing Co., New York (1980)).
[0869] The amount of compound to be administered is that amount
which is therapeutically effective. The dosage to be administered
will depend on the characteristics of the subject being treated,
e.g., the particular animal treated, age, weight, health, types of
concurrent treatment, if any, and frequency of treatments, and can
be easily determined by one skill in the art (e.g., by the
clinician). The standard dosing for protamine can be used and
adjusted (i.e., increased or decreased) depending upon the the
factors described above. The selection of the specific dose regimen
can be selected or adjusted or titrated by the clinician according
to methods known to the clinician to obtain the desired clinical
response.
[0870] The amount of a compound described herein that will be
effective in the treatment and/or prevention of a particular
disease, condition, or disorder will depend on the nature and
extend of the disease, condition, or disorder, and can be
determined by standard clinical techniques. In addition, in vitro
or in vivo assays may optionally be employed to help identify
optimal dosage ranges. The precise dose to be employed in the
compositions will also depend on the route of administration, and
the seriousness of the disorder, and should be decided according to
the judgment of the practitioner and each patient's circumstances.
However, a suitable dosage range for oral administration is,
generally, from about 0.001 milligram to about 200 milligrams per
kilogram body weight, from about 0.01 milligram to about 100
milligrams per kilogram body weight, from about 0.01 milligram to
about 70 milligrams per kilograms body weight, from about 0.1
milligram to about 50 milligrams per kilogram body weight, from 0.5
milligram to about 20 milligrams per kilogram body weight, or from
about 1 milligram to about 10 milligrams per kilogram body weight.
In some embodiments, the oral dose is about 5 milligrams per
kilogram body weight.
[0871] In some embodiments, suitable dosage ranges for intravenous
(i.v.) administration are from about 0.01 mg to about 500 mg per kg
body weight, from about 0.1 mg to about 100 mg per kg body weight,
from about 1 mg to about 50 mg per kg body weight, or from about 10
mg to about 35 mg per kg body weight. Suitable dosage ranges for
other modes of administration can be calculated based on the
forgoing dosages as known by those skilled in the art. For example,
recommended dosages for intradermal, intramuscular,
intraperitoneal, subcutaneous, epidural, sublingual, intracerebral,
intravaginal, transdermal administration or administration by
inhalation are in the range of from about 0.001 mg to about 200 mg
per kg of body weight, from about 0.01 mg to about 100 mg per kg of
body weight, from about 0.1 mg to about 50 mg per kg of body
weight, or from about 1 mg to about 20 mg per kg of body weight.
Effective doses may be extrapolated from dose-response curves
derived from in vitro or animal model test systems. Such animal
models and systems are well known in the art.
[0872] The compounds described herein can be formulated for
parenteral administration by injection, such as by bolus injection
or continuous infusion. The compounds can be administered by
continuous infusion subcutaneously over a period of about 15
minutes to about 24 hours. Formulations for injection can be
presented in unit dosage form, such as in ampoules or in multi-dose
containers, with an added preservative. The compositions can take
such forms as suspensions, solutions or emulsions in oily or
aqueous vehicles, and can contain formulatory agents such as
suspending, stabilizing and/or disposing agents. In some
embodiments, the injectable is in the form of short-acting, depot,
or implant and pellet forms injected subcutaneously or
intramuscularly. In some embodiments, the parenteral dosage form is
the form of a solution, suspension, emulsion, or dry powder.
[0873] For oral administration, the compounds described herein can
be formulated by combining the compounds with pharmaceutically
acceptable carriers well known in the art. Such carriers enable the
compounds to be formulated as tablets, pills, dragees, capsules,
emulsions, liquids, gels, syrups, caches, pellets, powders,
granules, slurries, lozenges, aqueous or oily suspensions, and the
like, for oral ingestion by a patient to be treated. Pharmaceutical
preparations for oral use can be obtained by, for example, adding a
solid excipient, optionally grinding the resulting mixture, and
processing the mixture of granules, after adding suitable
auxiliaries, if desired, to obtain tablets or dragee cores.
Suitable excipients include, but are not limited to, fillers such
as sugars, including, but not limited to, lactose, sucrose,
mannitol, and sorbitol; cellulose preparations such as, but not
limited to, maize starch, wheat starch, rice starch, potato starch,
gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and
polyvinylpyrrolidone (PVP). If desired, disintegrating agents can
be added, such as, but not limited to, the cross-linked polyvinyl
pyrrolidone, agar, or alginic acid or a salt thereof such as sodium
alginate.
[0874] Orally administered compositions can contain one or more
optional agents, for example, sweetening agents such as fructose,
aspartame or saccharin; flavoring agents such as peppermint, oil of
wintergreen, or cherry; coloring agents; and preserving agents, to
provide a pharmaceutically palatable preparation. Moreover, where
in tablet or pill form, the compositions may be coated to delay
disintegration and absorption in the gastrointestinal tract thereby
providing a sustained action over an extended period of time.
Selectively permeable membranes surrounding an osmotically active
driving compound are also suitable for orally administered
compounds. Oral compositions can include standard vehicles such as
mannitol, lactose, starch, magnesium stearate, sodium saccharine,
cellulose, magnesium carbonate, etc. Such vehicles are suitably of
pharmaceutical grade.
[0875] Dragee cores can be provided with suitable coatings. For
this purpose, concentrated sugar solutions can be used, which can
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments can be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0876] Pharmaceutical preparations which can be used orally
include, but are not limited to, push-fit capsules made of gelatin,
as well as soft, sealed capsules made of gelatin and a plasticizer,
such as glycerol or sorbitol. The push-fit capsules can contain the
active ingredients in admixture with fillers such as lactose,
binders such as starches, and/or lubricants such as talc or
magnesium stearate and, optionally, stabilizer. In soft capsules,
the active compounds can be dissolved or suspended in suitable
liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols. In addition, stabilizers can be added.
[0877] For buccal administration, the compositions can take the
form of, such as, tablets or lozenges formulated in a conventional
manner.
[0878] For administration by inhalation, the compounds described
herein can be delivered in the form of an aerosol spray
presentation from pressurized packs or a nebulizer, with the use of
a suitable propellant, such as dichlorodifluoromethane,
trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide
or other suitable gas. In the case of a pressurized aerosol the
dosage unit can be determined by providing a valve to deliver a
metered amount. Capsules and cartridges of, such as gelatin for use
in an inhaler or insufflator can be formulated containing a powder
mix of the compound and a suitable powder base such as lactose or
starch.
[0879] The compounds described herein can also be formulated in
rectal compositions such as suppositories or retention enemas, such
as containing conventional suppository bases such as cocoa butter
or other glycerides. The compounds described herein can also be
formulated in vaginal compositions such as vaginal creams,
suppositories, pessaries, vaginal rings, and intrauterine
devices.
[0880] In transdermal administration, the compounds can be applied
to a plaster, or can be applied by transdermal, therapeutic systems
that are consequently supplied to the organism. In some
embodiments, the compounds are present in creams, solutions,
powders, fluid emulsions, fluid suspensions, semi-solids,
ointments, pastes, gels, jellies, and foams, or in patches
containing any of the same.
[0881] The compounds described herein can also be formulated as a
depot preparation. Such long acting formulations can be
administered by implantation (for example subcutaneously or
intramuscularly) or by intramuscular injection. Depot injections
can be administered at about 1 to about 6 months or longer
intervals. Thus, for example, the compounds can be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0882] In yet another embodiment, the compounds can be delivered in
a controlled release system. In one embodiment, a pump may be used
(see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng., 1987, 14,
201; Buchwald et al., Surgery, 1980, 88, 507 Saudek et al., N.
Engl. J. Med., 1989, 321, 574). In another embodiment, polymeric
materials can be used (see Medical Applications of Controlled
Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla.
(1974); Controlled Drug Bioavailability, Drug Product Design and
Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger
et al., J. Macromol. Sci. Rev. Macromol. Chem., 1983, 23, 61; see,
also Levy et al., Science, 1985, 228, 190; During et al., Ann.
Neurol., 1989, 25, 351; Howard et al., J. Neurosurg., 1989, 71,
105). In yet another embodiment, a controlled-release system can be
placed in proximity of the target of the compounds described
herein, such as the liver, thus requiring only a fraction of the
systemic dose (see, e.g., Goodson, in Medical Applications of
Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other
controlled-release systems discussed in the review by Langer,
Science, 1990, 249, 1527-1533) may be used.
[0883] It is also known in the art that the compounds can be
contained in such formulations with pharmaceutically acceptable
diluents, fillers, disintegrants, binders, lubricants, surfactants,
hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers,
humectants, moisturizers, solubilizers, preservatives and the like.
The pharmaceutical compositions can also comprise suitable solid or
gel phase carriers or excipients. Examples of such carriers or
excipients include, but are not limited to, calcium carbonate,
calcium phosphate, various sugars, starches, cellulose derivatives,
gelatin, and polymers such as polyethylene glycols. In some
embodiments, the compounds described herein can be used with agents
including, but not limited to, topical analgesics (e.g.,
lidocaine), barrier devices (e.g., GelClair), or rinses (e.g.,
Caphosol).
[0884] In some embodiments, the compounds described herein can be
delivered in a vesicle, in particular a liposome (see, Langer,
Science, 1990, 249, 1527-1533; Treat et al., in Liposomes in the
Therapy of Infectious Disease and Cancer, Lopez-Berestein and
Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein,
ibid., pp. 317-327; see generally ibid.).
[0885] Suitable compositions include, but are not limited to, oral
non-absorbed compositions. Suitable compositions also include, but
are not limited to saline, water, cyclodextrin solutions, and
buffered solutions of pH 3-9.
[0886] The compounds described herein, or pharmaceutically
acceptable salts thereof, can be formulated with numerous
excipients including, but not limited to, purified water, propylene
glycol, PEG 400, glycerin, DMA, ethanol, benzyl alcohol, citric
acid/sodium citrate (pH3), citric acid/sodium citrate (pH5),
tris(hydroxymethyl)amino methane HCl (pH7.0), 0.9% saline, and 1.2%
saline, and any combination thereof. In some embodiments, excipient
is chosen from propylene glycol, purified water, and glycerin.
[0887] In some embodiments, the excipient is a multi-component
system chosen from 20% w/v propylene glycol in saline, 30% w/v
propylene glycol in saline, 40% w/v propylene glycol in saline, 50%
w/v propylene glycol in saline, 15% w/v propylene glycol in
purified water, 30% w/v propylene glycol in purified water, 50% w/v
propylene glycol in purified water, 30% w/v propylene glycol in
purified water, 50% w/v propylene glycol in purified water, 30% w/v
propylene glycol and 5 w/v ethanol in purified water, 15% w/v
glycerin in purified water, 30% w/v glycerin in purified water, 50%
w/v glycerin in purified water, 20% w/v Kleptose in purified water,
40% w/v Kleptose in purified water, and 25% w/v Captisol in
purified water. In some embodiments, the excipient is chosen from
50% w/v propylene glycol in purified water, 15% w/v glycerin in
purified water, 20% w/v Kleptose in purified water, 40% w/v
Kleptose in purified water, and 25% w/v Captisol in purified water.
In some embodiments, the excipient is chosen from 20% w/v Kleptose
in purified water, 20% w/v propylene glycol in purified water, and
15% w/v glycerin in purified water.
[0888] In some embodiments, the composition comprises 50 mg/mL of
compound in 20% w/v Kleptose in purified water.
[0889] In some embodiments, the formulation can be lyophilized to a
solid and reconstituted with, for example, water prior to use.
[0890] When administered to a mammal (e.g., to an animal for
veterinary use or to a human for clinical use) the compounds can be
administered in isolated form.
[0891] When administered to a human, the compounds can be sterile.
Water may be a suitable carrier when a compound is administered
intravenously. Saline solutions and aqueous dextrose and glycerol
solutions can also be employed as liquid carriers, particularly for
injectable solutions. Suitable pharmaceutical carriers also include
excipients such as starch, glucose, lactose, sucrose, gelatin,
malt, rice, flour, chalk, silica gel, sodium stearate, glycerol
monostearate, talc, sodium chloride, dried skim milk, glycerol,
propylene, glycol, water, ethanol and the like. The present
compositions, if desired, can also contain minor amounts of wetting
or emulsifying agents, or pH buffering agents.
[0892] The compositions described herein can take the form of a
solution, suspension, emulsion, tablet, pill, pellet, capsule,
capsule containing a liquid, powder, sustained-release formulation,
suppository, aerosol, spray, or any other form suitable for use.
Examples of suitable pharmaceutical carriers are described in
Remington's Pharmaceutical Sciences, A. R. Gennaro (Editor) Mack
Publishing Co.
[0893] In one embodiment, the compounds are formulated in
accordance with routine procedures as a pharmaceutical composition
adapted for administration to humans. Typically, compounds are
solutions in sterile isotonic aqueous buffer. Where necessary, the
compositions can also include a solubilizing agent. Compositions
for intravenous administration may optionally include a local
anesthetic such as lidocaine to ease pain at the site of the
injection. Generally, the ingredients are supplied either
separately or mixed together in unit dosage form, for example, as a
dry lophilized powder or water free concentrate in a hermetically
sealed container such as an ampoule or sachette indicating the
quantity of active agent. Where the compound is to be administered
by infusion, it can be dispensed, for example, with an infusion
bottle containing sterile pharmaceutical grade water or saline.
Where the compound is administered by injection, an ampoule of
sterile water for injection or saline can be provided so that the
ingredients may be mixed prior to administration.
[0894] The pharmaceutical compositions can be in unit dosage form.
In such form, the composition can be divided into unit doses
containing appropriate quantities of the active component. The unit
dosage form can be a packaged preparation, the package containing
discrete quantities of the preparations, for example, packeted
tablets, capsules, and powders in vials or ampules. The unit dosage
form can also be a capsule, cachet, or tablet itself, or it can be
the appropriate number of any of these packaged forms.
[0895] In some embodiments, a composition of the present disclosure
is in the form of a liquid wherein the active agent is present in
solution, in suspension, as an emulsion, or as a
solution/suspension. In some embodiments, the liquid composition is
in the form of a gel. In other embodiments, the liquid composition
is aqueous. In other embodiments, the composition is in the form of
an ointment.
[0896] Suitable preservatives include, but are not limited to,
mercury-containing substances such as phenylmercuric salts (e.g.,
phenylmercuric acetate, borate and nitrate) and thimerosal;
stabilized chlorine dioxide; quaternary ammonium compounds such as
benzalkonium chloride, cetyltrimethylammonium bromide and
cetylpyridinium chloride; imidazolidinyl urea; parabens such as
methylparaben, ethylparaben, propylparaben and butylparaben, and
salts thereof; phenoxyethanol; chlorophenoxyethanol;
phenoxypropanol; chlorobutanol; chlorocresol; phenylethyl alcohol;
disodium EDTA; and sorbic acid and salts thereof.
[0897] Optionally one or more stabilizers can be included in the
compositions to enhance chemical stability where required. Suitable
stabilizers include, but are not limited to, chelating agents or
complexing agents, such as, for example, the calcium complexing
agent ethylene diamine tetraacetic acid (EDTA). For example, an
appropriate amount of EDTA or a salt thereof, e.g., the disodium
salt, can be included in the composition to complex excess calcium
ions and prevent gel formation during storage. EDTA or a salt
thereof can suitably be included in an amount of about 0.01% to
about 0.5%. In those embodiments containing a preservative other
than EDTA, the EDTA or a salt thereof, more particularly disodium
EDTA, can be present in an amount of about 0.025% to about 0.1% by
weight.
[0898] One or more antioxidants can also be included in the
compositions. Suitable antioxidants include, but are not limited
to, ascorbic acid, sodium metabisulfite, sodium bisulfite,
acetylcysteine, polyquaternium-1, benzalkonium chloride,
thimerosal, chlorobutanol, methyl paraben, propyl paraben,
phenylethyl alcohol, edetate disodium, sorbic acid, or other agents
know to those of skill in the art. Such preservatives are typically
employed at a level of from about 0.001% to about 1.0% by
weight.
[0899] In some embodiments, the compounds are solubilized at least
in part by a solubilizing agent, Certain acceptable nonionic
surfactants, for example polysorbate 80, can be useful as
solubilizing agents, as can ophthalmically acceptable glycols,
polyglycols, e.g., polyethylene glycol 400 (PEG-400), and glycol
ethers.
[0900] Suitable solubilizing agents for solution and
solution/suspension compositions are cyclodextrins. Suitable
cyclodextrins can be chosen from .alpha.-cyclodextrin,
.beta.-cyclodextrin, .gamma.-cyclodextrin, alkylcyclodextrins
(e.g., methyl-.beta.-cyclodextrin, dimethyl-.beta.-cyclodextrin,
diethyl-.beta.-cyclodextrin), hydroxyalkylcyclodextrins (e.g.,
hydroxyethyl-.beta.-cyclodextrin,
hydroxypropyl-.beta.-cyclodextrin), carboxy-alkylcyclodextrins
(e.g., carboxymethyl-.beta.-cyclodextrin), sulfoalkylether
cyclodextrins (e.g., sulfobutylether-.beta.-cyclodextrin), and the
like. Ophthalmic applications of cyclodextrins have been reviewed
in Rajewski et al., Journal of Pharmaceutical Sciences, 1996, 85,
1155-1159. A cyclodextrin can optionally be present in an
ophthalmic composition at a concentration from about 1 to about 20
mg/ml, from about 5 to about 100 mg/ml, or from about 10 to about
50 mg/ml.
[0901] In some embodiments, the composition optionally contains a
suspending agent, For example, in those embodiments in which the
composition is an aqueous suspension or solution/suspension, the
composition can contain one or more polymers as suspending agents.
Useful polymers include, but are not limited to, water-soluble
polymers such as cellulosic polymers, for example, hydroxypropyl
methylcellulose, and water-insoluble polymers such as cross-linked
carboxyl-containing polymers.
[0902] One or more acceptable pH adjusting agents and/or buffering
agents can be included in the compositions, including acids such as
acetic, boric, citric, lactic, phosphoric and hydrochloric acids;
bases such as sodium hydroxide, sodium phosphate, sodium borate,
sodium citrate, sodium acetate, sodium lactate and
tris-hydroxymethylaminomethane; and buffers such as
citrate/dextrose, sodium bicarbonate and ammonium chloride. Such
acids, bases and buffers are included in an amount required to
maintain pH of the composition in an ophthalmically acceptable
range.
[0903] One or more acceptable salts can be included in the
compositions described herein in an amount required to bring
osmolality of the composition into an acceptable range. Such salts
include, but are not limited to, those having sodium, potassium or
ammonium cations and chloride, citrate, ascorbate, borate,
phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions.
In some embodiment, salts include sodium chloride, potassium
chloride, sodium thiosulfate, sodium bisulfite and ammonium
sulfate. In some embodiments, the salt is sodium chloride.
[0904] Optionally one or more acceptable surfactants, preferably
nonionic surfactants, or co-solvents can be included in the
compositions to enhance solubility of the components of the
compositions or to impart physical stability, or for other
purposes. Suitable nonionic surfactants include, but are not
limited to, polyoxyethylene fatty acid glycerides and vegetable
oils. e.g., polyoxyethylene (60) hydrogenated castor oil; and
polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol
10, octoxynol 40; polysorbate 20, 60 and 80;
polyoxyethylene/polyoxypropylene surfactants (e.g., Pluronic.RTM.
F-68, F84 and P-103); cyclodextrin; or other agents known to those
of skill in the art. Typically, such co-solvents or surfactants are
employed in the compositions at a level of from about 0.01% to
about 2% by weight.
[0905] One or more lubricating agents can also be included
optionally in the compositions. Such agents include, but are not
limited to, polyvinyl alcohol, methylcellulose, hydroxypropyl
methylcellulose, polyvinylpyrrolidone, and the like.
[0906] Compositions of the present disclosure typically include a
combination of one or more of the optional excipients listed above.
For example, in some embodiments, the ophthalmic composition can
optionally further comprise glycerin in an amount from about 0.5%
to about 5%, from about 1% to about 2.5%, or from about 1.5% to
about 2% by weight. Glycerin can be useful to increase viscosity of
the composition and for adjustment of osmolality. Independently of
the presence of glycerin, the composition can also further comprise
a cyclodextrin, such as hydroxypropyl-.beta.-cyclodextrin, in an
amount from about 0.5% to about 2.5% by weight, as a solubilizing
agent, and an antimicrobially effective amount of a preservative,
e.g., imidazolidinyl urea in an amount from about 0.03% to about
0.5%; methylparaben in an amount from about 0.015% to about 0.25%;
propylparaben in an amount from about 0.005% to about 0.01%;
phenoxyethanol in an amount from about 0.25% to about 1%; disodium
EDTA in an amount from about 0.05% to about 0.2%; thimerosal in an
amount from 0.001% to about 0.15%; chlorobutanol in an amount from
about 0.1% to about 0.5%; and/or sorbic acid in an amount from
about 0.05% to about 0.2%; all by weight.
[0907] The compounds described herein can also be incorporated into
compositions such as, for example, polishes, paints, sprays, or
detergents formulated for application to a surface to inhibit the
growth of a Candida or Aspergillus species thereon. These surfaces
include, but are not limited to, countertops, desks, chairs,
laboratory benches, tables, floors, bed stands, tools, equipment,
doorknobs, windows, and the like. The compounds described herein
can also be incorporated into soaps and hand lotions. The present
compositions, including the cleansers, polishes, paints, sprays,
soaps, and detergents, can contain one or more of the compounds
described herein. In addition, the compositions can optionally
contain one or more of each of the following: solvents, carriers,
thickeners, pigments, fragrances, deodorizers, emulsifiers,
surfactant, wetting agents, waxes, and/or oils. For example, in
some embodiments, the compounds can be incorporated into a
formulation for external use as a pharmaceutically acceptable skin
cleanser, particularly for the surfaces of human hands. Cleansers,
polishes, paints, sprays, soaps, hand lotions, and detergents and
the like containing the compounds described herein can be useful in
homes and institutions, particularly but not exclusively, in
hospital settings for the prevention of nosocomial infections.
[0908] The present disclosure also provides pharmaceutical packs or
kits comprising one or more containers filled with one or more
compounds described herein. Optionally associated with such
container(s) can be a notice in the form prescribed by a
governmental agency regulating the manufacture, use or sale of
pharmaceuticals or biological products, which notice reflects
approval by the agency of manufacture, use or sale for human
administration for treating a condition, disease, or disorder
described herein. In some embodiments, the kit contains more than
one compound described herein. In some embodiments, the kit
comprises a compound described herein in a single injectable dosage
form, such as a single dose within an injectable device such as a
syringe with a needle.
[0909] The present disclosure also provides methods of inhibiting
the growth of a Candida or Aspergillus species comprising
contacting the Candida or Aspergillus species with one or more
compounds described above, or a pharmaceutically acceptable salt
thereof. In some embodiments, the compound can act as an antiseptic
agent for cleansing surfaces, such as in, for example, kitchens and
bathrooms. In these embodiments, the compound can be formulated for
such uses by procedures well known to the skilled artisan.
[0910] The present disclosure also provides methods of treating a
mammal having oral candidiasis comprising administering to the
mammal in need thereof an effective amount of one or more compounds
described above, or a pharmaceutically acceptable salt thereof. In
some embodiments, the mammal can be pre-diagnosed with oral
candidiasis prior to treatment. In some embodiments, no formal
diagnosis may have been made; in such embodiments, the mammal may
be suspected of having oral candidiasis for which treatment is
recognized as being desirable.
[0911] In some embodiments, the yeast is, or the oral or
disseminated candidiasis infection is due to, Candida albicans,
Candida glabrata, Candida tropicalis, or Candida krusei.
[0912] The present disclosure also provides one or more compounds
described above, or a pharmaceutically acceptable salt thereof, or
a pharmaceutical composition comprising one or more compounds
described above, for treating candidiasis (oral and/or
disseminated) or an Aspergillus infection.
[0913] The present disclosure also provides one or more compounds
described above, or a pharmaceutically acceptable salt thereof, or
a pharmaceutical composition comprising one or more compounds
described above, for use in the manufacture of a medicament for
treating candidiasis (oral and/or disseminated) or an Aspergillus
infection.
[0914] The present disclosure also provides the use of one or more
compounds described above, or a pharmaceutically acceptable salt
thereof, or a pharmaceutical composition comprising one or more
compounds described above, in the inhibition of growth of a Candida
or Aspergillus species.
[0915] The present disclosure also provides the use of one or more
compounds described above, or a pharmaceutically acceptable salt
thereof, or a pharmaceutical composition comprising one or more
compounds described above, for treating candidiasis (oral and/or
disseminated) or an Aspergillus infection in a mammal.
[0916] In some embodiments, the compositions are administered with
an anti-microbial agent, such as, e.g., an anti-bacterial,
anti-fungal, anti-mold, or anti-viral agent. For example, the
anti-microbial agent can be a second compound disclosed herein, or
the anti-microbial agent can be another anti-microbial agent such
as, for example, an antibiotic selected from the group consisting
of aminoglycosides, cephalosporins, diaminopyridines,
fluoroquinolones, sulfonamides and tetracyclines. Examples of
useful antibiotics which can serve as additional anti-microbials
include, but are not limited to, amikacin, azithromycin, cefixime,
cefoperazone, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone,
chloramphenicol, ciprofloxacin, clindamycin, colistin,
domeclocycline, doxycycline, erythromycin, gentamicin, mafenide,
methacycline, minocycline, neomycin, norfloxacin, ofloxacin,
oxytetracycline, polymyxin B, pyrimethamine, silver sulfadiazine,
sulfacetamide, sulfisoxazole, tetracycline, tobramycin, and
trimethoprim.
[0917] In those embodiments in which the composition is
administered with an anti-microbial agent, the present disclosure
provides administration at the same time or sequentially, of a
composition comprising one or more of the compounds disclosed
herein and a separate composition of the anti-microbial agent, in a
treatment regimen intended to provide a beneficial effect from
co-action of the two types of anti-microbial agents.
"Co-formulation" herein means that the compound and the additional
anti-microbial agent are administered as components of a single
composition.
[0918] Any medicament having utility in treating oral candidiasis
can be used in co-therapy, co-administration, or co-formulation
with a composition described above. Such additional medicaments
include, but are not limited to, anti-inflammatory agents (e.g.,
steroidal anti-inflammatory agents, non-steroidal anti-inflammatory
agents (NSAIDs), and selective cyclooxygenase-2 inhibitors);
topical and/or regional anesthetic agents; anti-allergic agents
(e.g., anti-histamines); demulcents; acetylcholine blocking agents;
adrenergic agonists, beta-adrenergic blocking agents and other
anti-glaucoma agents; anti-hypertensives; anti-cataract agents;
anti-microbial agents, and anti-allergic agents.
[0919] Examples of suitable non-steroidal anti-inflammatory agents
include, but are not limited to, prostaglandin H synthetase
inhibitors (Cos I or Cox II), also referred to as cyclooxygenase
type I and type II inhibitors, such as diclofenac, flurbiprofen,
ketorolac, suprofen, nepafenac, amfenac, indomethacin, naproxen,
ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam,
sulindac, mefanamic acid, diflusinal, oxaprozin, tolmetin,
fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone,
aspirin, oxyphenbutazone, tenoxicam and carprofen; cyclooxygenase
type II selective inhibitors, such as vioxx, celecoxib, etodolac;
PAF antagonists, such as apafant, bepafant, minopafant, nupafant
and modipafant; PDE IV inhibitors, such as ariflo, torbafylline,
rolipram, filaminast, piclamilast, cipamfylline, and roflumilast;
inhibitors of cytokine production, such as inhibitors of the NFkB
transcription factor; or other anti-inflammatory agents know to
those skilled in the art.
[0920] Examples of suitable topical or regional anesthetic agents
include, but are not limited to, benzocaine.
[0921] Examples of suitable anti-allergic agents include, but are
not limited to, pemirolast, olopatadine, and the corticosteroids
(prednisolone, fluorometholone, loteprenol and dexamthasone).
[0922] Frequency of administration is typically such that the
dosing interval, for example, the period of time between one dose
and the next, during waking hours is from about 2 to about 12
hours, from about 3 to about 8 hours, or from about 4 to about 6
hours. It will be understood by those of skill in the art that an
appropriate dosing interval is dependent to some degree on the
length of time for which the selected composition is capable of
maintaining a concentration of the compound(s) in the lacrimal
fluid and/or in the target tissue (e.g., the conjunctiva) above the
MIC.sub.90 (the minimum concentration of the oligomer or polymer
which inhibits microbial growth by 90%). Ideally the concentration
remains above the MIC.sub.90 for at least 100% of the dosing
interval. Where this is not achievable it is desired that the
concentration should remain above the MIC.sub.90 for at least about
60% of the dosing interval, or should remain above the MIC.sub.90
for at least about 40% of the dosing interval.
[0923] The activity of anti-microbials is generally expressed as
the minimum concentration of a compound (active agent) required to
inhibit the growth of a specified pathogen. This concentration is
also referred to as the "minimum inhibitory concentration" or
"MIC". The term "MIC.sub.90" refers to the minimum concentration of
an antimicrobial active agent required to inhibit the growth of
ninety percent (90%) of the tested isolates for one particular
organism. The concentration of a compound required to totally kill
a specified bacterial species is referred to as the "minimum
bactericidal concentration" or "MBC."
[0924] In some embodiments, an effective concentration of the
compound in the composition will generally be from about 0.01% to
about 20% by weight (wt %) of the composition, from about 0.05% to
about 10% by weight, from about 0.1% to about 8.0% by weight, from
about 0.5% to about 5.0% by weight, from about 1.0% to about 5.0%
by weight, or from about 2.0% to about 4.0% of the composition.
[0925] In some embodiments, the animal being treated, such as a
human, is "in need thereof." That is, the animal is in need of
treatment. Thus, in some embodiments, the animal is treated for the
purpose of preventing or treating the Candida or Aspergillus
infection. In some embodiments, the animal has been diagnosed with
a Candida or Aspergillus infection or is suspected of having a
Candida or Aspergillus infection. In some embodiments, the animal,
or human, is in a population at risk of having a Candida or
Aspergillus infection, such as in a prison or hospital.
[0926] In order that the present disclosure may be more efficiently
understood, examples are provided below. It should be understood
that these examples are for illustrative purposes only and are not
to be construed as limiting the disclosure in any manner.
Throughout these examples, molecular cloning reactions, and other
standard recombinant DNA techniques, were carried out according to
methods described in Maniatis et al., Molecular Cloning--A
Laboratory Manual, 2nd ed., Cold Spring Harbor Press (1989), using
commercially available reagents, except where otherwise noted.
EXAMPLES
Example 1
Screen for Anti-Candida Activity
[0927] Over 800 compounds were screened at a single concentration
of 10 .mu.M against a clinical isolate of C. albicans GDH2346 (see,
triangles in FIG. 1 below), and an additional 400 compounds were
screened with 11 concentrations to give an IC.sub.50 (see, green
squares in FIG. 1 below). The activity was determined at 24 and 48
hours by OD.sub.600 and fluorescence.
[0928] 106 compounds showed greater than 90% inhibition, giving a
hit rate of 12%. These compounds are all cidal. 109 compounds
showed an IC.sub.50<5 .mu.g/mL and an additional 90 had an
IC.sub.50<10 .mu.g/mL.
Example 2
Activity Against Hyphae
[0929] C. albicans (GDH2346) was grown in 10% FCS for 3 days to
achieve hyphae. Hyphae were treated with Compound 100 (8 .mu.g/mL)
for 0 minutes (see, FIG. 2A), 15 minutes (see, FIG. 2B), 30 minutes
(see, FIG. 2C), or 60 minutes (see, FIG. 2D). Cultures were stained
with FungaLight Live-Dead stain (InVitrogen) and observed under
fluorescence microscopy (100.times. magnification).
[0930] Compound 100 rapidly caused death of hyphal cultures at low
concentrations.
Example 3
Permeabilization
[0931] (A) C. albicans GDH2346 was treated with Compound 100 at the
concentrations indicated (.mu.g/mL) for 30 minutes, followed by
staining with PI and quantification by flow cytometry. Ethanol
treatment was used to establish 100% uptake.
[0932] (B) Cells were treated with Compound 100 at 32 .mu.g/mL for
the times indicated.
[0933] To determine whether the compounds act at the membrane, like
many host defense proteins, or intracellularly like histatins, the
ability of Compound 100 to cause membrane permeability was
assessed. Dose-dependent membrane permeabilization of Candida, as
shown by cellular accumulation of PI, was evident within 30 minutes
at 8 to 32 .mu.g/mL Compound 100 concentrations (see FIG. 3A).
Influx was rapid, where >75% of cells were permeabilized after a
5-minute treatment with Compound 100 at 32 .mu.g/mL (see FIG.
3B).
Example 4
Cellular Efflux-ATP Release
[0934] (A) C. albicans GDH2346 was treated with either Compound 100
or histatin 5 for 30 minutes, followed by the separation of the
extracellular medium and the cells. Intracellular and extracellular
ATP levels were quantified by luciferase assay and measurement in a
luminometer, relative to a standard control. Treatment 1=no
treatment; Treatment 2=16 .mu.g/mL Compound 100; Treatment 3=32
.mu.g/mL Compound 100; and Treatment 4=Histatin 5 (1 mg/mL).
[0935] (B) Time dependent release of ATP of cells treated with
Compound 100 at 32 .mu.g/mL.
[0936] (C) Dose response of cells treated for 30 minutes, followed
by quantification of extracellular ATP.
[0937] To demonstrate efflux, effects of Compound 100 on ATP
release were examined. Cells were treated with either Compound 100
or Histatin 5, and levels of intracellular and extracellular ATP
were measured after 30 minutes. At 32 .mu.g/mL Compound 100, almost
all of the ATP from the cell was extracellular, which exceeded
efflux with 1 mg/mL of histatin 5 (see, FIG. 4A).
[0938] At 32 .mu.g/mL, ATP efflux was rapid with significant
extracellular accumulation occurring by 20 minutes following
treatment (see, FIG. 4B).
[0939] Efflux was also dose-dependent over 30 minutes of exposure
time, with detectable ATP levels evident at 16 .mu.g/mL (see, FIG.
4C).
Example 5
IC.sub.50 Profiles
[0940] Candida IC.sub.50s were determined by OD.sub.600 and
fluorescence from vegetative cells and by MTS viability assay in
the hyphal state. MICs were determined using a broth microdilution
assay under standard CLSI conditions Bacteria strains: E. coli
25922 (EC), S. aureus 27660 (SA), E. faecalis 29212 (EF), P.
aeruginosa 10145 (PA), and K. pneumoniae 13883 (KP). Cytotoxicity
(EC.sub.50) was determined against mouse 3T3 fibroblasts, human
transformed liver HepG2 cells, and human oral keratinocyte cell
line, OKF6/TERT using an MTS viability assay. Candida
IC.sub.50s<10 .mu.g/mL, MICs<5 .mu.g/mL and cytotoxicity
EC.sub.50s>100 .mu.M are indicated in green. MICs>5 .mu.g/mL
and cytotoxicity EC.sub.50s<100 .mu.M are indicated in red.
Results are shown in Table 1 below.
TABLE-US-00001 TABLE 1 Compound Activity 100 114 136 138 135 137
115 IC50 Candida, 4.93 7.57 4.24 4.10 1.44 1.89 4.74 Vegetative
IC50 Candida, 4.90 3.17 0.71 7.50 2.68 2.29 4.07 Hyphal (.mu.g/ml)
EC50 EC (.mu.g/ml) 1.56 >50 >50 >50 6.25 50 >50 EC50 SA
0.78 50 0.39 >50 12.5 25 >50 EC50 EF (.mu.g/ml) 0.78 25 0.098
>50 12.5 25 >50 EC50 PA 3.13 >50 50 >50 >50 50
>50 EC50 KP 1.56 >50 50 >50 12.5 >50 >50 IC50 NIH3T3
(.mu.M) 439 543 311 406 436 83 358 IC50 HepG2 >1000 255 453 502
885 182 >1000 IC50 OKF6/ >1000 172 466 491 766 42 309 TERT
(.mu.M)
Example 6
IC.sub.50 Profiles
[0941] Candida IC.sub.50s (CA) were determined by OD.sub.600 and
fluorescence from vegetative cells. MICs were determined using a
broth microdilution assay under standard CLSI conditions Bacteria
strains: E. coli 25922 (EC), S. aureus 27660 (SA), E. faecalis
29212 (EF), P. aeruginosa 10145 (PA), and K. pneumoniae 13883 (KP).
Cytotoxicity (EC.sub.50) was determined against mouse 3T3
fibroblasts and human transformed liver HepG2 cells using MTS
viability assay. Results are shown in Table 2 below.
TABLE-US-00002 TABLE 2 CA 3T3 HepG2 EC SA EF PA KP Compound
.mu.g/mL .mu.M .mu.M .mu.g/mL .mu.g/mL .mu.g/mL .mu.g/mL .mu.g/mL
139 >100 117 3.10 118 3.64 40 90 119 6.17 140 3.58 159 99 0.78
0.195 3.13 3.13 3.13 141 107 62 12.5 12.5 100 25 142 1.65 131 100
3.13 1.56 6.25 25 3.13 143 6.48 222 140 3.13 0.39 1.56 50 6.25 144
3.95 80 188 3.13 0.098 0.195 3.13 6.25 145 23.94 >1000 790
>50 25 3.13 50 >50 146 44.59 307 341 50 0.39 0.39 12.5 >50
147 1.56 0.098 0.39 6.25 1.56 148 8.74 450 312 25 3.13 >50
>50 >50 149 >100 29 20 3.13 0.049 1.56 >100 3.13 150
3.34 54 58 0.78 0.049 1.56 3.13 3.13 151 3.85 56 78 3.13 0.195 6.25
6.25 12.5 152 3.77 34 12 1.56 0.39 1.56 3.13 1.56 153 46 65 12.5
1.56 12.5 100 12.5 154 1.88 451 853 1.56 0.39 6.25 12.5 6.25 155
2.63 12.5 0.39 >50 12.5 >50 156 1.94 487 >1000 1.56 1.56
>50 12.5 >50 157 6.21 228 3.13 0.39 12.5 12.5 12.5 158 17.47
179 615 1.56 1.56 >50 25 >50 159 2.11 61 64 0.78 0.78 3.13
6.25 3.13 160 1.48 28 28 1.56 1.95 3.13 6.25 3.13 161 11.8 356 466
1.56 6.25 >50 50 6.25 162 3.12 49 273 1.56 0.39 12.5 3.13 3.13
163 1.79 31 113 3.13 3.13 3.13 50 25
Example 7
Efficacy In a Mouse Model of Oral Candidiasis
[0942] 8-week old male mBD-1 (-/-) mice on a C57B1/6 background
were pre-treated for 5 days with 2.5 mg/mL oral tetracycline to
reduce normal oral flora (n=5 per group; n=4 for nystatin group).
Day 0: infection initiated by oral inoculation of a 50 .mu.L
suspension of C. albicans (clinical isolate GDH2346 at
5.times.10.sup.7 cfu/mL) onto a cotton ball after lightly scoring
the tongues. Day 3: Single topical administration of test agent (10
mg/mL) applied in 0.05 mL hydrogel. Tissue was harvested 24 hours
post-treatment, homogenized, and quantitated by serial dilution and
plating.
[0943] Compound 100 nearly sterilized the infected tongue following
a single topical dose and was 50-fold more efficacious than
Nystatin. Results are shown in FIG. 5A. (Treatment 1=Control;
Treatment 2=Compound 100 at 10 mg/mL; and Treatment 3=Nyststin at
10 mg/mL). FIG. 5B is a photomicrograph of a 10 .mu.m section of a
tongue from an infected mouse on day 4, stained with PAS
(Magnification=100.times.). Arrows show hyphae and hyphal insertion
into tissue.
Example 8
Anti-Candida Activity; In Vitro Profiles
[0944] Candida MIC assays were determined in accordance with CLSI
guidelines M27-A3using a clinically isolated C. albicans strain,
GDH2346. 50% human serum was added to determine activity in the
presence of serum.
[0945] For determination of anti-Candida IC.sub.50s, the method was
modified by using RPMI/MOPS buffer pH 6.3 and by addition of FDGlu,
a substrate for the yeast enzyme exoglucanase which is secreted
during cell growth. This provides a fluorescent readout for cell
growth which was used in addition to the traditional optical
density measure of growth. OD.sub.600 and fluorescence were
determined at 24 and 48 hours and the average of all 4 reads was
used for the final IC.sub.50 determination.
[0946] To form the biofilm, yeast were grown in RPMI/MOPS, 0.4%
sucrose pH7.4 media supplemented with 10% FBS in tissue
culture-treated flat bottom 96 well plates for 48 hours. The
filamentous yeast cultures were then vigorously washed to remove
any non-filamentous, non-attached yeast. The remaining attached
filamentous biofilm yeast were incubated in saline containing
serially diluted compounds for 24 hours. The cultures were
aspirated to remove compound, rinsed and overlayed with RPMI/MOPS,
0.4% sucrose pH7.4 media, Biofilm viability was measured using a
cell proliferation assay (CellTiter96 Aqueous Kit from Promega) and
IC50s were determined using Prism GraphPad software (nonlinear fit,
Table 3).
[0947] Time kills were performed in the same manner as IC.sub.50s.
At each time point yeast were removed, diluted as necessary and
plated on YPD agar to determine viable CFUs.
[0948] Bacteria MICs were determined using a broth microdilution
assay under standard CLSI conditions Bacteria strains: clinical
isolates; yeast strains: C. dubliniensis (NCPF3949), C. glabrata
(ATCC 90030), C. krusei (ATCC 6258), C. parapsilosis (ATCC 22019),
and C. tropicalis (ATCC 750). Cytotoxicity (EC.sub.50) was
determined against mouse 3T3 fibroblasts, human transformed liver
HepG2 cells, and human oral keratinocyte cell line, OKF6/TERT using
an MTS viability assay.
[0949] Table 3 shows potent activity of several compounds against
vegetative and 2-day hyphal biofilm cultures.
TABLE-US-00003 TABLE 3 Anti-C. albicans GDH2346 (.mu.g/ml) Compound
Vegetative Hyphal 164 4.88 11.04 100 4.93 4.90 136 4.24 0.71 135
1.44 2.68 185 1.09 1.00 186 1.03 1.40 187 2.20 ND 188 2.08 2.22
[0950] FIGS. 6A and 6B show cidal activity with rapid killing
kinetics of Compound 100 and Compound 135, respectively.
[0951] Table 4 shows a subset of compounds active in serum.
TABLE-US-00004 TABLE 4 MIC (.mu.g/ml) Cmpd 136 + Cmpd 135 +
Compound Cmpd 136 50% HS Cmpd 135 50% HS C. albicans 4 2 4 2
GDH2346 C. dubliniensis 8 2 4 1 C. glabrata 4 1 2 2 HS = human
serum
Example 9
Activity Against Commensal Bacteria in Oral Acvity and Yeast
[0952] Table 5 shows the activity of several compounds against
commensal bacteria and different yeast.
TABLE-US-00005 TABLE 5 Commensal Bacteria Other Yeast Species MIC
(.mu.g/ml) MIC (.mu.g/ml) S. A. C. C. C. C. C. C. Cmpd salivarius
viscosis tropicalis parapsilosis dubliniensis glabrata krusei
albicans 100 >64 >64 4 8 8 16 8 4-8 136 16 4 4-8 4-8 8 4 32 4
135 >64 >64 2-4 2 4 2 16 4 137 >64 >64 4 4-8 8-16 8 8 8
185 8 4 0.5 2 2 2 2 2 186 8 4 0.5 2 2 2 2 2 187 32 8 0.5 4 4 4 4 2
188 64 16 0.5 4 4 4 4 2
Example 10
Anti-Fungal Activity; Efficacy in Mouse Candida Sepsis Model
[0953] Mice were made neotropenic with i.p. injections of
cyclophosphamide (150 mg/kg in 10 mL/kg) at 4 and 1 day before
inoculation. Each animal was then inoculated by injecting 0.1 mL of
inoculum of C. albicans in a tail vein. The standard was
administered orally and the test compounds by IV 1 hour after
infection.
[0954] The kidneys were collected from four mice in Group 1 at 1
hour after infection and from the remaining mice in the study at 24
hours after infection. Kidneys were combined in a sterile tube. An
aliquot of sterile PBS were added to each tube and the contents
homogenized with a tissue homogenizer. Serial dilutions of the
tissue homogenates were conducted, 0.1 mL aliquots were spread on
SDA plates and the plates incubated at 35.degree. C. overnight. The
CFU/kidneys were determined from colony counts. One-way ANOVA with
Bonferroni Multiple Comparisons Test was performed using GraphPad
Instat version 3.00 for Windows 95, GraphPad Software, San Diego
Calif. USA.
[0955] FIG. 7 shows Compound 135 has cidal activity with
.gtoreq.1.5 log.sub.10 reductions in tissue burden from treatment
onset. In contrast, FIG. 8 shows that current triazole and
anti-fungals have a static effect in the model.
Example 11
Disseminated Candidiasis Model; Survival Sturdy
[0956] Mice were made neutropenic with i.p. injections of
cyclophosphamide (150 mg/kg in 10 mL/kg) at 4 and 1 day before
inoculation. Each animal was then inoculated by injecting 0.1 mL of
inoculum of C. albicans in a tail vein. At 2 hours post-infection,
the standard was administered orally and the test compound by IV.
Compounds were dosed once daily for 4 days.
[0957] The kidneys were collected from four mice in Group 1 at 2
hours after infection, from four mice in Groups 2-5 at five days
after infection, and from all surviving mice in the infected
treatment groups. An aliquot of sterile PBS were added to each tube
and the contents homogenized with a tissue homogenizer. Serial
dilutions of the tissue homogenates were conducted, 0.1 mL aliquots
were spread on SDA plates and the plates incubated at 35.degree. C.
overnight. The CFU/kidneys were determined from colony counts.
[0958] Survival data was analyzed using the log-rank (Mantel-Cox)
test and one-way ANOVA with Tukey's Multiple Comparisons Test was
performed on the yeast density and change in body weight data
(GraphPad InStat version 5.04).
[0959] FIG. 9 shows survival of mice over a 14-day period.
p<0.01 between Fluconazole and Compound 135 (10 mg/kg) and
p<0.01 between Fluconazole and Compound 135 (15 mg/kg).
Example 12
Anti-Aspergillus Activity
[0960] The in vitro efficacy of a library of compounds was assessed
for antifungal activity against A. niger (AN1), A. fumigatus
(A1163) and A. flavus (NRRL3357) and compared to that of
Itraconazole. For a subset of compounds selected based upon
efficacy in the screening study a full MIC profile was
conducted.
[0961] Efficacy of test articles was determined in RPMI 1640 broth
with MOPS buffered to pH7.2 in accordance with CLSI guidelines
M38-A for Antifungal Susceptibility Testing of Filamentous Fungi.
The method was modified by using flat well plates to allow
microscopic identification of growth. The final screening
concentration of each test article was 10 .mu.M. Assay plates were
incubated aerobically at 37.degree. C. for 24-48 hours. Following
incubation, plates were assessed visually (by eye and
microscopically) for inhibition of growth. Inhibition was recorded
at 50%, 80% and 100% inhibition compared to the positive control. A
hit was described as a well demonstrating 100% inhibition.
[0962] MICs were determined in RPMI 1640 broth plus MOPS buffered
to pH7.2 in accordance with CLSI guidelines M38-A for Antifungal
Susceptibility Testing of Filamentous Fungi. The method was
modified by using flat well plates to allow microscopic
identification of growth. The final MIC range was 64-0.125
.mu.g/mL.
[0963] Table 6 shows several compounds have broad anti-fungal
activity with low mammalian cell cytotoxicity.
TABLE-US-00006 TABLE 6 IC.sub.50 Cytotoxicity % Inhibition
(.mu.g/ml) EC.sub.50 (.mu.M) A. A. A. C. Mouse Human Compound
fumigatus niger flavus albicans 3T3 HepG2 Cmpd 184 100 100 100 3.1
1000 155 Cmpd 183 100 100 100 2.0 478 1000 Cmpd 136 100 100 100 1.4
311 453 Cmpd 165 80 100 100 1.1 115 138
[0964] Various modifications of the disclosure, in addition to
those described herein, will be apparent to those skilled in the
art from the foregoing description. Such modifications are also
intended to fall within the scope of the appended claims. Each
reference (including, but not limited to, journal articles, U.S.
and non-U.S. patents, patent application publications,
international patent application publications, gene bank accession
numbers, and the like) cited in the present application is
incorporated herein by reference in its entirety.
* * * * *